Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

Ragusa

Ragusa Minerals Limited

Premium
Information Technology

Ragusa Minerals is a Perth-based micro-cap exploration shell. Over 2025–26 it has repositioned itself as a single-asset, US-focused manganese–gold explorer. Its only material asset is an approximately 60% controlling stake in Pegasus Tel, Inc., a dormant former payphone company quoted on the OTC market. Pegasus holds the roughly 4,142-acre Purple Pansy Manganese-Gold Project in the Aguila Mining District, about 80 km northwest of Phoenix, Arizona. The investment case rests on two things: the US government treating manganese as a federally designated critical mineral, with zero domestic mine supply, and the company's early-stage evidence of high-grade manganese oxide at the historic Black Rock open-cut. That evidence comes from rock chips of 44.6–45.6% Mn and 14 induced-polarisation drill targets. The company has no revenue, no Mineral Resource on its current asset, about A$246k of cash at 30 June 2026 and an auditor's going-concern emphasis. It is therefore a high-risk, financing-dependent option on drilling success and on US critical-mineral policy tailwinds. --- ### Company's own description (FY2026 Annual Report, paraphrased) In the FY2026 Directors' Report, the board gives the group's principal activity as mineral exploration and project evaluation. It reports no significant change in the nature of that activity. Ragusa describes itself as an Australian-based mineral exploration company whose interest in the Purple Pansy Project in Arizona is held through its approximately 60% stake in Pegasus Tel Inc. The board says its development strategy is to position Purple Pansy as a cornerstone US manganese and gold asset in a mining-friendly jurisdiction. The asset is presented as direct leverage to manganese, a federally designated US critical mineral, and to gold. The company also says it is reviewing new projects across commodities and jurisdictions. Its standard corporate boilerplate states a mission of maximising shareholder value through focused, data-driven, risk-weighted exploration and development. ### Independent characterisation | Dimension | Characterisation | |---|---| | Business model | Grassroots and early-stage mineral exploration. The aim is to define a JORC Mineral Resource and then monetise it by development, joint venture or sale. | | Revenue model | None. Income is limited to interest on cash (A$2,560 in FY2026) and one-off accounting gains. There is no product, service, subscription or licensing revenue. | | Funding model | Equity placements to sophisticated and professional investors under ASX Listing Rules 7.1/7.1A, with free-attaching options | | Value-chain position | Upstream: exploration of raw mineral endowment. No mining, processing or marketing capability. | | Prospective customers | If ever developed: steelmakers (the dominant manganese end use), battery-grade manganese chemical refiners (HPMSM and EMM producers) and US defence-industrial users. Gold would go to refiners and offtakers. None exist today. | | End markets (prospective) | Steel and alloy (ferromanganese and silicomanganese), lithium-ion battery cathodes (LMFP, NMC and LMR chemistries), defence materials, precious metals | | Corporate structure | Parent: Ragusa Minerals Ltd. Wholly owned subsidiary: Stradun Australia Pty Ltd. Controlled entity: Pegasus Tel, Inc. (Delaware; ~60.09%), with Purple Pansy claims held by PTEL. PTEL also historically owned Blue Bull Ventures B.V. (Netherlands). | Ragusa is best described as a capital-markets vehicle that recycles its ASX listing across successive exploration options. Since its 2020 conversion from a financial-services shell (SIV Asset Management) it has held and then abandoned gold in Zimbabwe (Lonely Mine), gold in Alaska (Monte Cristo), halloysite-kaolin-REE in Western Australia (Burracoppin), and lithium in the Northern Territory (NT Lithium farm-in). It has now concentrated on manganese–gold in Arizona. Between FY2023 and FY2026 it wrote off about A$4.95m of capitalised exploration and business development spend. Over FY2024–FY2025 it also impaired about A$1.53m of loans to subsidiaries that were later deconsolidated. ### Pegasus Tel, Inc. legacy business Third-party profiles describe Pegasus Tel as a provider of outdoor payphone services. Through Blue Bull Ventures B.V., it historically also offered European venture-capital and advisory services. PTEL's unaudited FY2024 financial statements filed with the SEC (Form C-AR) show nil assets, liabilities of US$39,405, nil revenue and nil expenses for 2023 and 2024. On those figures the telecom business was dormant before Ragusa's involvement. Some data aggregators still describe Ragusa as providing telecommunication services.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2010
Perth, Australia

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
Quest

Quest for Growth Belgium

Premium
Information Technology

Quest for Growth is one of Belgium's few listed private-equity-style vehicles open to retail investors. As a public privak it offers daily-tradable, tax-efficient exposure to three segments: European listed small- and mid-caps (≈59% of NAV at mid-2026), venture and growth funds largely managed by Capricorn Partners (≈31%), and direct venture/growth investments (≈9%), across three themes — digital, healthtech and cleantech. After a difficult 2022–2025 period in venture valuations, the fund announced a strategic reorientation in late 2025 back to its founding mission, trimming large-cap listed positions and returning EUR 1 per share (EUR 18.7M) via a capital reduction in March 2026. Co-founder Jos Peeters became reference shareholder in 2025 after buying Belfius Insurance's stake. The shares trade at a historically wide discount of around 50% to NAV, versus a ten-year average near 27%. --- ### Company's own description In its NAV releases, Quest for Growth describes its diversified portfolio as mostly invested in growth companies listed on European stock exchanges, in venture and growth capital, and in venture and growth funds, focusing on innovative companies. Its 2026 investor material lists the investment case as diversified segments, diversified themes (cleantech, healthtech, digitalisation), daily tradability, favourable public-privak tax status, and a significant discount to NAV (analyst presentation, 31 Jul 2026). ### Business model and "revenue" model | Income line | FY2023 (EUR M) | FY2024 (EUR M) | FY2025 (EUR M) | |---|---|---|---| | Net realised gains/(losses) on financial assets | -6.19 | -5.77 | 4.00 | | Net unrealised gains/(losses) | 2.48 | -0.28 | -6.26 | | Dividend income | 1.82 | 2.16 | 2.14 | | Net interest income | 0.08 | 0.14 | 0.05 | | Total income from investments | -1.80 | -3.75 | -0.08 | QFG earns returns, not sales. Its income consists of: (FY2025 annual results press release.) Costs are dominated by a flat management fee to Capricorn Partners (EUR 1.48M p.a. in 2023–2025). There is no product, subscription or licensing revenue. ### Value-chain position, customers, end-markets QFG is a capital provider: (i) a minority portfolio investor in listed European small/mid-caps; (ii) a limited partner in Capricorn-managed funds (and selectively third-party funds such as Fortino Ventures III); (iii) a co-investor alongside those funds in direct venture rounds. Its "customers" are its shareholders — largely Belgian retail investors seeking tax-efficient access to private markets. End-markets of portfolio companies: industrial technology, healthcare/medtech, software/AI, cleantech and sustainable chemistry. ### Independent characterisation QFG is a sub-scale (≈EUR 110M NAV) closed-end fund whose fixed management fee (~1.4–1.5% of NAV) and persistent discount have weighed on shareholder returns: the ten-year share holding-period return to 30 Jun 2026 was −20.4%, versus +13.9% for NAV (analyst presentation). Its strongest asset is a disciplined listed-equity book with long-term winners (Nexus, Melexis, Wolters Kluwer); its weakest is a venture/fund book heavily exposed to cleantech and SaaS valuations, which has been marked down repeatedly. The late-2025 capital return and reorientation are a direct response to the discount problem.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1998
Leuven, Belgium
Queen's

Queen's Road Capital Investment Ltd.

Premium
Information Technology

Queen's Road Capital is a Hong Kong-headquartered, TSX-listed, dividend-paying investment company that functions as a specialist financier to the global mining sector. It deploys permanent balance-sheet capital primarily into structured convertible debentures of advanced-stage and producing resource companies. These instruments typically carry high cash-and-share coupons (8–12%), upfront establishment fees and equity conversion rights, so QRC earns a contractual yield while retaining equity upside. It concentrates on what management calls the highest-quality assets globally, with stated exposure of roughly 50% uranium, 25% copper and 25% precious metals (FY2025 earnings release). Its anchor position is NexGen Energy, developer of the Rook I/Arrow uranium project in Saskatchewan. NexGen was QRC's first investment and is now one of its largest holdings. Led by former CIBC mining banker Warren Gilman, QRC reported record FY2025 after-tax earnings of US$115 million and trades at a low earnings multiple, reflecting its mark-to-market, concentration-heavy model. --- ### Company's own description The company describes itself in every release as a dividend-paying, leading financier to the global resource sector and a resource-focused investment company. It invests in both privately held and publicly traded companies. It acquires and holds securities for long-term capital appreciation, focusing on convertible debt securities and on resource projects in advanced development or production located in politically safe jurisdictions (standard "About" paragraph, press releases 2025–2026; company website home page). ### Independent characterization QRC is best understood as a permanent-capital, listed mezzanine/convertible lender to mid-cap and junior miners. It is not a mining operator, a royalty company or a fund manager. It has no third-party fee-earning AUM, no products in the conventional sense and no customers in the conventional sense. Its "customers" are the investee companies that issue debentures to it, and its "revenue" is investment income. The economic engine has four layers: 1. **Contractual income.** Coupons on the convertible debenture book are about 9.7% on average on a US$223 million book, generating about US$22 million of annual interest income (portfolio update, 16 September 2025; FY2025 earnings release, 17 November 2025). Coupons are frequently split between cash and shares. For example, the Gold Royalty debenture pays 7.0% cash and 3.0% shares; Moxico pays 7.5% cash and 3.5% shares; Contango pays 6.0% cash and 2.0% shares. 2. **Establishment fees.** Fees are typically 3% of principal (Adriatic, Contango, Gold Royalty, Moxico releases). The ATHA transaction included a fee paid in 1,552,900 ATHA shares (release 5 February 2026). 3. **Fair-value gains and losses** on the embedded conversion options and on equity positions, recognized through earnings. This explains the extreme quarter-to-quarter volatility in reported EPS (C$3.74 in the February 2026 quarter versus a loss of C$1.62 in the May 2026 quarter; finanzen.net via Parqet). 4. **Realized gains on conversion or takeover.** Examples are the Adriatic debenture converted at A$2.7976 and the subsequent Dundee Precious Metals takeover; the IsoEnergy conversion at C$3.52 against a share price of C$12.46; and the Los Andes conversion at C$10.82 (releases 16 September 2025; Los Andes, 18 March 2026). ### Revenue model mix | Revenue type | Description | Approximate weight | |---|---|---| | Interest income (cash and in-kind shares) | Coupons on convertible debentures | About US$22m per year run-rate (Sept/Nov 2025 company statements) | | Establishment and other fees | Typically 3% upfront on new debentures | Episodic; not separately disclosed | | Dividend income | From equity holdings (e.g., NexGen pays no dividend; not material) | Not material / not disclosed | | Net change in fair value | Unrealized gains/losses on debentures' conversion features and equities | Dominant driver of earnings (FY2025 NI US$115m vs about US$22m interest) | | Realized gains | Conversions, takeovers, disposals | Episodic | There is no product, subscription or licensing revenue. ### Value-chain position QRC sits in the capital-provision layer of the mining value chain. It provides capital after discovery and resource definition but alongside or ahead of project finance, typically at the stages of permitting, construction, expansion or early production. It competes with equity markets, streaming and royalty financing, private credit funds and offtake prepayments. Its differentiation is speed, a single decision-maker structure and a willingness to take large tickets of US$20–70 million in a single instrument with voting-alignment and standstill covenants (NexGen 2020 and 2023 terms; mining.com coverage of NexGen financing). ### End-markets served | End-market (commodity) | Representative investees | Stated share of exposure | |---|---|---| | Uranium (nuclear fuel) | NexGen Energy, IsoEnergy, ATHA Energy | About 50% (FY2025 release, Nov 2025) | | Copper | Moxico Resources (Zambia), Los Andes Copper (Chile) | About 25% | | Precious metals (gold, silver) | Gold Royalty, Contango ORE, Challenger (Hualilan gold), Adriatic (exited via Dundee takeover) | About 25% |

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2011
Queen's Road Central, Hong Kong
QrfComm.VA

Qrf Comm. VA

Premium
Information Technology

Qrf NV is a small-cap Belgian REIT specialising in dominant inner-city commercial real estate: shops, leisure and food-and-beverage space on the main high streets and shopping hubs of Belgium's strongest cities, notably Antwerp, Ghent, Brussels, Ostend and Hasselt. After exiting the Netherlands in 2024 and selling non-core assets, the company rebuilt its growth path. In 2025 it bought a 15-asset high-street portfolio and the Feest- en Cultuurpaleis in Ostend. In June 2026 it acquired a 50% stake in The Mint, the Brussels shopping hub on the Muntplein. Its combined economic portfolio reached MEUR 368 across 44 sites and 149 tenants at mid-2026, generating MEUR 22.1 of contractual rent. The strategy has three parts: active value creation through redevelopment (Zara in Ostend, McDonald's in Ghent), disciplined acquisitions that are neutral or accretive to EPRA earnings, and a stable EUR 0.84 dividend. The shares trade at a persistent discount of about 30–35% to EPRA NTA. --- ### Company self-description (latest filings, paraphrased) The company describes itself as a public Belgian regulated real estate company (GVV/BE-REIT) focused on inner-city real estate in Belgium. It acquires, redevelops and leases commercial property for retail, leisure and hospitality (horeca) [S1 FY2025]. In its AGM 2026 presentation it summarises the proposition as investing in dominant commercial real estate in Belgium's most resilient cities [S9]. The H1-2026 report adds that Qrf gives retail and institutional investors access to a professionally managed portfolio of inner-city commercial real estate in Belgian city centres [S2]. ### Business model Qrf is a pure rental-income landlord operating inside the BE-REIT tax regime. Its economics work as follows: **Revenue model:** Almost all revenue is contractual rent from commercial leases (FY2025 rental income KEUR 13,123) [S1]. There is no product, subscription or licensing revenue. Small ancillary flows include recharged service charges and property taxes (passed through and roughly neutral) and, since 2023–24, sales of solar power to tenants. The solar contribution was guided at about KEUR 50 for 2024, rising to about KEUR 100 per year at full roll-out [S3 FY2023]. **Lease structure:** Belgian commercial leases run for at least nine years under the Commercial Lease Act of 30 April 1951. Tenants have a mandatory right to terminate at each three-year interval with six months' notice, and up to three renewal rights of nine years each. Rents are normally paid monthly in advance and indexed annually. Tenants usually post bank guarantees of three to six months' rent [S2 H1-2026]. **Value-chain position:** Qrf sits at the ownership and asset-management layer. Since 1 January 2020 it has run property management in-house; before that, management was outsourced to Quares [S10, 2019 PR]. Since 2021 it has pursued redevelopment more actively: capex-led repositioning and build-to-suit projects such as Veldstraat 88 and Langemunt in Ghent and the Feest- en Cultuurpaleis in Ostend [S1; S2]. **Ownership vehicles:** Assets are held directly or through 100% subsidiaries: RIGS NV, RAB Invest NV, City 25 NV, Immo Feest en Cultuurpaleis Oostende NV, and the dormant Qrf Nederland BV. Arioso Investments Belgium NV was merged into Qrf NV on 3 July 2026. Joint ventures are equity-accounted: Ardeno BV (30%, Century Center Antwerp, with Baltisse) and Toleda Invest NV and Portici NV (50% each, The Mint Brussels, with AG Real Estate) [S2]. **Capital model:** As a REIT, Qrf must distribute most of its earnings. Growth is therefore financed by new equity (contributions in kind 2015–2019, cash raises in October 2025 and July 2026) and by bank debt within the legal 65% debt-ratio ceiling. Bank covenants cap the debt ratio at 60%, and a financial plan is required above 50% [S2]. ### Customer types and end-markets Named tenants include Inditex/Zara (Ostend), HEMA, Wibra and Action (Korenmarkt, Ghent), McDonald's (Langemunt, under construction), Kruidvat, Proximus, Etam, Xandres, Max Mara, Manfield, Tezenis/Calzedonia, Bouvy, Lola & Lisa, Lab 9, O'Tacos, April Beauty and Meet Me There. Through The Mint JV, tenants include Uniqlo, HEMA, Decathlon and Medi Market [S1; S2]. INNO occupies a large department store in Hasselt [S3]. The Belgian State occupies the State Archives in Bruges on a lease running to 2037 [S2]. The top-10 tenants accounted for 44% of combined contractual rent at 30 June 2026, down from 52% at year-end 2025 [S2]. ### Independent characterisation Qrf is a sub-scale but newly re-energised high-street REIT. From 2021 to 2024 it was in balance-sheet repair: it sold the Dutch portfolio, out-of-town assets and JV stakes, cutting the debt ratio from 53.6% to 43.6%. From late 2025 it switched to an acquisitive growth model, funded by two discounted rights-style capital increases (EUR 9.62 and EUR 9.90 per share, against EPRA NTA of roughly EUR 15–16). Management defends this by targeting accretion to EPRA earnings per share and NTA-positive revaluations from redevelopment, accepting short-term NTA dilution [S2]. The investment case now depends on four things: integrating The Mint, executing the Ghent redevelopments, re-letting the vacant Meirbrug unit in Antwerp, and whether larger scale can narrow the persistent 30–35% discount to NTA.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2013
Ghent, Belgium
Prosperity

Prosperity International Holdings (H.K.) Limited

Premium
Information Technology

Prosperity International Holdings (H.K.) Limited was a Hong Kong-headquartered, Bermuda-domiciled diversified group that evolved from an Asian clinker and cement trading house into a capital-intensive conglomerate spanning iron ore mining and trading (Malaysia, Brazil), a minority stake in an Indonesian cement producer, and Chinese property investment and development concentrated in Jiangsu and Guangdong. The pivot from asset-light trading to asset-heavy mining and property, financed with short-term bank debt, bonds, guaranteed notes and convertible bonds, coincided with the 2014–2016 iron ore price collapse and later a tightening Chinese property credit environment. By FY2019 the group was recording losses approaching HK$2 billion, by November 2019 it had entered Bermuda provisional liquidation for restructuring purposes, and by FY2020 its auditor disclaimed an opinion. Trading was suspended in July 2021 and the listing cancelled in February 2023. Its residual relevance is as a case study in leverage, cyclical commodity exposure and governance strain. --- ### Company's own description (Annual Report 2020) In its FY2020 Report of the Directors, the company described itself as an investment holding company whose core business comprised three reportable segments: (i) real estate investment and development; (ii) mining and trading of iron ore and raw materials; and (iii) trading of clinker, cement and other building materials. In the clinker business, the company characterised itself as a leading Asian trading organisation specialising in clinker, cement and granulated blast furnace slag, sourcing predominantly from the Far East and Southeast Asia and supplying customers across Asia Pacific. Its customer base was described as operators of cement plants, cement grinding mills and cement terminals, together with construction-material trading agents. Revenue was recognised as sales of goods to customers net of discounts and returns, plus rental income from real estate leasing. ### Independent characterisation By the time of its last filings the business was best understood not as an operating conglomerate but as a distressed asset-realisation vehicle. Each segment was in a different stage of wind-down: **Property:** was the only segment generating meaningful gross margin in FY2020 (HK$881m of revenue, largely from handing over pre-sold units at the One City project in Binhai County, Yancheng, Jiangsu). However, management was simultaneously selling equity stakes in projects and investment properties to raise cash, and contractors had sued for unpaid construction costs. **Iron ore:** had been reduced to small-scale third-party trading. The wholly owned Sri Jaya mine and processing plant in Pahang, Malaysia had been suspended since 2015; its operational mining scheme expired during FY2019 without renewal; the 85%-held Brazil mine was under a disposal agreement (US$4.5m) signed April 2019. Trading revenue collapsed after the group ceased the activity in the second half of FY2020. **Clinker and cement trading:** was the most resilient line (HK$200m in H1 FY2021 versus HK$225m a year earlier), but it is a thin-margin, working-capital-intensive intermediary business that depends on letters of credit and bank trade lines — precisely the facilities a defaulting group struggles to maintain. ### Business and revenue model mix | Revenue type | Nature | Segment | Model | |---|---|---|---| | Sales of goods — iron ore & raw materials | Point-in-time recognition, USD-denominated, documentary credit at sight | Mining & trading of iron ore | Product trading (low margin) | | Sales of goods — clinker, cement, slag | Point-in-time, USD-denominated, irrevocable L/C, 0–90 day terms | Clinker & cement trading | Product trading / intermediation | | Sales of properties | Point-in-time on delivery of units | Real estate | Development-for-sale (project-based) | | Rental income | Operating leases of 1–10 years on investment properties | Real estate | Recurring rental | | Others | Miscellaneous | All other segments | — | There was no subscription or licensing revenue. The model was entirely product-sale and rental based. ### Value chain position and end-markets | Segment | Value chain position | Customer types | End-markets | |---|---|---|---| | Clinker & cement trading | Midstream intermediary between Chinese/Southeast Asian producers and import markets | Cement plants, grinding mills, terminals, trading agents | Asia Pacific construction (historically also Africa, Europe, Taiwan, Oceania) | | Iron ore | Upstream (mine ownership, suspended) and midstream (trading) | Steel mills and traders (primarily PRC) | Chinese steel production | | Indonesia Conch (25% FVTPL investment) | Upstream cement manufacturing | Indonesian construction market | Indonesia | | Real estate | Developer and landlord | Residential buyers in tier-3/4 Jiangsu cities; commercial tenants in Guangzhou | PRC residential and commercial property |

Revenue$0.3B
Employees171
Market CapN/A
FoundedN/A
Wan Chai, Hong Kong
Primeserv

Primeserv Group Limited

Premium
Information Technology

Primeserv Group Limited is a JSE-listed investment holding company. Through about a dozen South African subsidiaries, it provides what it calls "Integrated Business Support Services." These are human-capital-centric services covering: - temporary and permanent staffing; - project and artisan staffing; - productivity and functional outsourcing; - payroll and wage-bureau services; - accredited training and learnerships; - HR, IR and consulting services; - related fulfilment services such as PPE and time-and-attendance. At R1.1bn of FY2026 revenue it is a small-cap specialist, roughly one-eleventh the size of the sector leader Adcorp. Its core is logistics, distribution, warehousing, wholesale/retail, heavy transport, engineering, mining and petrochemical project work. The model is low-gross-margin (about 12%) and asset-light. It is ungeared, holds R109.5m of cash and is founder-controlled. The CEO and founder holds 19.1% of the issued shares, and treasury/trust structures hold a further 35%. Over FY2022–FY2026 the group compounded EPS at 26.5% a year against revenue growth of 9.0% a year, through margin expansion, cost discipline and steady share buybacks. It nonetheless trades at roughly 0.8× book value, because liquidity is extremely thin. --- ### Company's own description (latest annual report) The FY2026 Integrated Report describes Primeserv as a JSE-listed company focused on innovative, customised, client-centric Integrated Business Support Services across many industries and sectors. Its stated goal is to raise clients' capabilities, efficiencies, productivity and performance by optimising human capital. The services focus on implementing, managing and measuring human capital, supported by web-based systems. They comprise: - specialised staffing services; - functional outsourcing and productivity services; - skills training and consulting; - related fulfilment and support services. The Directors' Report in the FY2026 AFS describes the company as an investment holding company whose trading activities are conducted through subsidiaries. The offering includes human capital management and consulting, productivity and functional outsourcing, permanent and temporary employment staffing, training and skills development, and related fulfilment services. Results are reported in two segments: Integrated Business Support Services and Shared Services. ### Business model and revenue model | Revenue recognition basis | FY2025 (R'000) | FY2026 (R'000) | |---|---|---| | Services rendered over time | 1073532 | 1095538 | | Services rendered at a point in time | 752 | 829 | | Total revenue | 1074284 | 1096367 | Primeserv is almost entirely a services business. It has no product, subscription or licensing revenue of any significance. **Revenue streams per the AFS accounting policy:** **Temporary employment services (TES):** Billed at an hourly rate per assignee, linked to the assignee's pay. Recognised over time as hours are worked. This is the dominant stream. **Permanent placement fees:** Usually a percentage of the candidate's remuneration. Recognised when employment starts. **Consulting fees:** As agreed with the client. Recognised over time or at a point in time. **Training fees:** As agreed with the client. Recognised over time. **PPE recharge:** Personal protective equipment is bought for assignees, held as "contract cost assets" (R2.3m at FY2026 year-end) and recharged to clients as a monthly fee. **Outcome-based productivity services:** Under Primeserv Productivity Services, clients pay per unit of functional output delivered. **Why gross margin is low.** Cost of sales (R962.0m in FY2026) consists of "payroll, training, consulting and associated costs." Most revenue is therefore a pass-through of assignee wages. Gross margin was 12.3% in FY2026 and operating margin 3.5%. This is structurally typical of South African TES operators. ### Value chain position Primeserv sits between labour supply (the pool of largely semi-skilled and youth job seekers) and corporate and public-sector demand for flexible labour. It acts as legal employer of record for assignees. It takes on the compliance burden: Labour Relations Act section 198 obligations, bargaining councils, SETA-accredited training, B-BBEE and POPIA. Its differentiation claims rest on four things: - national branch coverage; - industry-specialist operating units; - a proprietary client-management framework, INTHRGRATE™, offered at no extra cost; - B-BBEE credentials, which matter in South African procurement scoring. ### Customer types and end-markets The FY2026 Integrated Report names its customers as local businesses and corporations, multinationals, government, state-owned enterprises and municipal-owned entities. It lists 30 sectors served: agriculture, automotive, banking, building and construction, design and draughting, drivers and transportation, engineering and fabrication, facilities management, financial and insurance, FMCG, food production, government services, harbours and railways, hospital/nursing/medical, logistics and distribution centres, mechanical, mega-projects, merchandising, mining, paper and pulp, petrochemical, pharmaceutical, power generation, retail and wholesale, secretarial and office support, tourism and hospitality, telecoms, telemarketing and call centres, warehousing, and waste management. For financial reporting, revenue is disaggregated into seven sector buckets: - construction support services; - engineering and mining project support services; - general business support services; - industrial and manufacturing support services; - logistics and distribution support services; - petrochemicals support services; - wholesale and retail support services. The FY2026 CEO report names the operating units as follows: 1. specialist staffing support for logistics, distribution, warehousing and wholesale/retail; 2. staffing support for manufacturing and construction; 3. heavy transport and freight staffing (the Pinnacle acquisition); 4. specialised project and artisan staffing for engineering, petrochemical and mining; 5. training services. ### Independent characterisation Strip away the integrated-services language and Primeserv is a South African temporary-staffing and labour-outsourcing operator with: - a high concentration of revenue in two subsidiaries. Primeserv Staff Dynamix (R543.6m revenue in FY2026, 25.1% minority interest) and Primeserv Denverdraft (R350.5m, 51.4% effective minority interest) together account for roughly 82% of group revenue on an unconsolidated, pre-elimination basis (FY2026 AFS note 23); - a valuable but small adjacent training and consulting capability; - a balance sheet that is effectively a cash-rich, ungeared working-capital funder for client payroll cycles. Earnings quality is driven by three things: gross-margin management on contracts, debtor discipline (trade receivables were R146.2m at FY2026 year-end), and Shared Services cost control. Shared Services ran at a loss of about R18m a year, effectively the head-office cost.

Revenue$0.1B
EmployeesN/A
Market CapN/A
Founded1997
Sandton, South Africa
Premier

Premier Fishing & Brands Limited

Premium
Information Technology

Premier Fishing and Brands is a vertically integrated, black-owned and black-managed South African seafood group with roots going back to 1952. It holds 15-year commercial fishing rights, granted in March 2022, in South Coast rock lobster, squid, pilchards, anchovy, deep-sea trawl hake and hake longline. It also participates in West Coast rock lobster. It farms abalone at Gansbaai and markets an organic liquid fertiliser (Seagro). Its competitive identity rests on niche, high-value export species rather than volume. It claims leadership in South Coast rock lobster (about 60% of the SA market, exported to the US) and is South Africa's largest squid exporter to Europe through its 80.65% stake in Port Elizabeth (Gqeberha)-based Talhado. At about ZAR 0.5bn of annual revenue it is a niche player next to Oceana and Sea Harvest. It has been unlisted since August 2023 and is controlled by the Sekunjalo group. Its banking-access dispute and limited post-2022 disclosure define its current risk profile. --- ### Company's own description (latest annual report, FY2022) The FY2022 directors' report describes the group as engaged in the commercial harvesting, processing and marketing of marine resources in South Africa. Its principal operations are catching, processing and marketing pelagic fish (pilchards and anchovy), West Coast rock lobster, South Coast rock lobster, squid and hake. It also earns revenue from cold and dry storage, farms abalone, and manufactures environmentally friendly organic liquid fertiliser (FY2022 Group AFS, Directors' Report §1). The group's revenue-recognition policy adds processing, marketing and distribution services performed for third parties, mainly small quota holders, and quota-usage revenue (FY2020 Group AFS, note 1.16). ### Business model Premier controls the value chain from resource access to the export customer: 1. **Resource access (rights).** Government-allocated fishing rights under the Marine Living Resources Act. Total Allowable Catch (TAC) or Total Allowable Effort (TAE) is set annually by the Department of Forestry, Fisheries and the Environment (DFFE). Premier was granted all its major rights for 15 years in March 2022 under FRAP 2021 (FY2022 AFS). 2. **Harvesting.** An owned and jointly operated fleet of more than 30 vessels (IOL Business Report, Nov 2022). The vessels' carrying value was ZAR 199.4 M at FY2022 (AFS note 3). Talhado alone operated 17 vessels at acquisition in 2017 and more than 15 in 2023. 3. **Processing and cold chain.** Lobster processing (tails, whole raw or cooked frozen, live), squid sea-freezing and land freezing (Talhado cold room capacity of about 800 tonnes), abalone canning, and third-party cold storage. 4. **Aquaculture.** Marine Growers (Pty) Ltd abalone farm at Gansbaai, Western Cape. Expansion targeted holding or production capacity rising from about 120 tonnes to about 300 to 350 tonnes a year (IOL, May 2020; SeafoodSource, 2021). 5. **Sales and marketing.** Premfresh Seafoods (Pty) Ltd is the group sales and marketing arm. Since June 2024 it has also run domestic retail stores (Plumstead, Hout Bay and Gansbaai) and an online store. 6. **Third-party services.** Catching, processing and marketing for small, mainly black-owned West Coast rock lobster quota holders. This feeds volume through Premier's plants and brands. ### Revenue model mix - **Product sales (estimated well over 90% of revenue, not formally disclosed):** export of lobster, squid, abalone and hake. Domestic sale of pilchards and anchovy (industrial fish), fertiliser and retail seafood. **Services:** processing and marketing fees and cold-storage rental. **Quota usage revenue:** recognised when a customer is granted an unconditional right to quota (FY2020 AFS, note 1.16). **Subscription or licensing:** none. ### Value-chain position, customers and end-markets **Position:** upstream (rights-holder and harvester) through to midstream (processor and exporter), with a small downstream retail presence since 2024. **Customer types:** foreign importers and distributors (US lobster importers, Southern European squid buyers, Asian abalone traders), domestic fishmeal and canning buyers for pilchards and anchovy, agricultural users for Seagro, and retail consumers through PremFresh. **End-markets:** United States (South Coast rock lobster under the South Atlantic Lobster brand), Southern Europe (squid under Sea Diamond and Talhado: Spain, Portugal, France, Italy), East Asia (abalone and lobster: China, Hong Kong, Taiwan, Japan), plus the UK, Australia and South Africa (IOL, Oct 2022; FY2022 AFS note 6). **Export payment terms:** customers generally pay upfront before shipment, which keeps credit risk low (FY2022 AFS, accounting policy 1.24). ### Independent characterisation Premier is best understood as a portfolio of small, high-value, resource-constrained export fisheries attached to a fixed-cost asset base (vessels, plants and an abalone farm). Earnings are driven by three largely exogenous variables: - **squid catch rates**, which swung revenue by ±ZAR 100 M in FY2020 to FY2023; - **EUR/ZAR and USD/ZAR exchange rates**; and **TAC settings:** Management actions such as cost control and vessel maintenance matter at the margin. The model generated an operating margin of about 11% in a good year (FY2019) and 2 to 3% in poor squid years (FY2020 to FY2022). The core strategic asset is the 15-year rights portfolio and B-BBEE credentials. The core strategic liability since 2021 is the group's association with Sekunjalo, which has triggered sustained bank de-risking.

Revenue$0.0B
Employees1,000
Market CapN/A
Founded1952
United States, North America
PPLUS

PPLUS Trust Series GSC-2 GSC 2 CT FL RT

Premium
Information Technology

PPLUS Trust Series GSC-2 is a 2004-vintage Merrill Lynch repackaging vehicle. It turns a long-dated, fixed-rate, deferrable Goldman Sachs trust-preferred security into a $25-par, exchange-listed, quarterly-paying floating-rate instrument for retail and income investors. The trust holds $35 million of Goldman Sachs Capital I 6.345% Capital Securities due February 2034. It swaps the fixed 6.345% coupon with a Merrill Lynch (now Bank of America) entity for three-month USD LIBOR plus 0.85%, subject to a 3.00% floor and an 8.00% cap. Since the 2023 LIBOR cessation, the economics are consistent with the statutory replacement of three-month Term SOFR plus a 0.26161% spread adjustment. Investors therefore take two exposures: **Credit:** Goldman Sachs subordinated hybrid credit, now rated BB+ by S&P at certificate level. **Counterparty:** Bank of America-group swap counterparty risk. They receive short-rate-linked income with roughly 7.3 years to final maturity. The vehicle is passive, static and unmanaged. --- **What the vehicle does.** PYT is a static grantor trust. Its only function is to hold deposited assets, collect payments, exchange cash flows under a swap, and pass net receipts to certificateholders. The 2004 prospectus supplement describes the deposited assets as the underlying securities plus an ISDA swap agreement that the depositor assigned to the trust. The prospectus states that the trustee will not manage the underlying securities. Disposal is permitted only on: - a payment default; - an acceleration; or - the underlying issuer ceasing to file Exchange Act reports. **Business model and cash-flow mechanics.** 1. **Collateral.** The trust holds $35,000,000 of GS Capital I 6.345% Capital Securities. They pay semi-annually on 15 February and 15 August, so the trust receives $1,110,375 every six months, or $2,220,750 a year. The Feb 2014, Aug 2014, Feb 2026 and Aug 2026 trustee reports all show exactly $1,110,375 received per semi-annual date. 2. **Swap.** On each semi-annual collection date, the trust pays the fixed interest received to the swap counterparty. On each quarterly distribution date (15 Feb, May, Aug, Nov), the counterparty pays the floating "interest distribution amount". Payments are netted in practice. For example, on 17 Aug 2026 the trust received $1,110,375 from GS, paid a net $675,118.97 to Merrill Lynch International, and distributed $435,256.03 to holders. 3. **Floating coupon.** The rate is three-month USD LIBOR + 0.85%, floored at 3.00% and capped at 8.00%, reset quarterly (424B5, 2004). In the off-coupon quarters (May and November), the full distribution comes from the swap counterparty. In May 2014, for example, the trust received $250,833.33 under the swap and nothing from the underlying. 4. **Principal.** Holders receive the underlying principal at final maturity on 15 February 2034. An earlier redemption of the underlying, or exercise of third-party call warrants, can return principal sooner. **Revenue model.** For the trust, "revenue" is fixed coupon income from the underlying ($2.22 million a year). "Distributable income" is the floating swap receipt. There is no product, service, subscription or licensing revenue. **Value-chain position.** PYT sits in the structured-retail-notes ("repack") layer of the capital markets: - GS Group issues junior subordinated debentures to GS Capital I. - GS Capital I issues capital securities to institutional investors. - A Merrill Lynch affiliate buys a $35 million slice in the secondary market (about 1.273% of the $2.75 billion issue). - Merrill Lynch Depositor deposits that slice into the PPLUS trust. - The trust issues $25 certificates distributed by Merrill Lynch, Pierce, Fenner & Smith. **Customer types and end-markets.** The certificates target US retail and high-net-worth income investors, preferred-stock and income funds, and brokerage accounts that want $25-par exchange-listed instruments. The minimum initial lot was 40 certificates; block buyers of 250,000+ received a reduced price of $24.75. **Company's own description (paraphrased from 424B5 and 8-K/10-K boilerplate).** The certificates represent undivided beneficial interests in a trust whose assets are principally the underlying securities and the swap. They are not obligations of the depositor or its affiliates, nor direct obligations of the underlying issuer. Investors are directed to GS Group's own Exchange Act reports. Neither the depositor nor the trustee has investigated the underlying issuer's creditworthiness. **Independent characterization.** PYT is effectively a synthetic Goldman Sachs floating-rate trust preferred with an embedded 3% floor, 8% cap, third-party call, and counterparty-risk overlay. Its value drivers are: 1. GS subordinated credit spreads; 2. the level and path of three-month SOFR; 3. Bank of America-group counterparty credit; 4. the probability of GS redeeming the 6.345% securities early, or of call-warrant exercise; 5. thin secondary-market liquidity (30-day average volume of about 641 certificates, Equibles, July 2026).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2004
NY, US
Playmates

Playmates Holdings Limited

Premium
Information Technology

Playmates Holdings is a family-controlled Hong Kong investment holding company whose economics rest on three very different engines. The first and most valuable on a balance-sheet basis is a Hong Kong-centric investment property portfolio—anchored by The Toy House on Canton Road, residential units at Hillview in the Mid-Levels and an industrial building in Tuen Mun—carried at HK$3.87bn at 30 June 2026. The second is a 50.85% controlling stake in Playmates Toys, a 60-year-old licensed-toy specialist that historically earned outsized returns from Teenage Mutant Ninja Turtles but loses that licence on 31 December 2026. The third is a small, liquid listed-equity portfolio of roughly HK$110m. The group carries net cash of about HK$915m and trades near 0.22x attributable book value. Its investment case is therefore a deep-value, asset-backed story whose realisation depends on Hong Kong property valuations stabilising and the toy business rebuilding a post-Turtles licence portfolio. --- ### The company's own description In its FY2025 annual results, the company describes the group as principally engaged in the design, development, marketing and distribution of toys and family entertainment activity products, together with property investment, property management and investment holding, with turnover representing revenue from these activities [S1]. It reports three segments: (i) property investments and management businesses, which lease commercial, industrial and residential premises for rental income, seek long-term capital appreciation and earn property management fees; (ii) the investment business, which holds financial instruments, principally listed equities, for dividend and interest income and capital gains; and (iii) the toy business, which designs, develops, markets and distributes toys and family entertainment activity products [S1, S4]. ### Independent characterisation | Engine | Model | Revenue type | Capital intensity | Cyclicality driver | |---|---|---|---|---| | Property investment | Owns and leases HK retail/office, residential and industrial space; small UK/US/Japan holdings | Recurring rental (lease) income | Low maintenance capex; high embedded capital | HK retail footfall, office supply glut, interest rates | | Property management | Fee income on group-owned buildings; day-to-day services outsourced to Savills | Service fees | Minimal | Occupancy | | Toy business (PTL) | Asset-light licensed toy designer/marketer; outsources manufacturing; pays royalties to IP owners | Product sales (point-in-time) | Low fixed; working-capital seasonal | Entertainment release calendar, licence tenure, US tariffs, retailer inventory | | Investment business | Liquid listed-equity portfolio (US mega-cap tech plus HK names) | Dividends, interest, mark-to-market | N/A | Equity markets | | Revenue stream | FY2025 HK$m | % of group | |---|---|---| | Sale of toys (product) | 512.2 | 77.0 | | Rental income from investment properties (lease) | 132.2 | 19.9 | | Property management income (service) | 19.5 | 2.9 | | Dividend and interest income (investment) | 1.3 | 0.2 | | Total | 665.2 | 100.0 | Economically, Playmates Holdings is best understood as a property holding company with a consolidated, volatile, licence-driven toy subsidiary bolted on. The toy business dominates revenue (77% of FY2025 group revenue, 70% of H1 2026) [S1, S4], but the property portfolio dominates assets (investment properties of HK$3.87bn versus group total assets of HK$5.34bn at 30 June 2026) and has driven the reported bottom line via non-cash revaluation deficits in every year from 2021 to 2025 [S1, S2, S3, S4]. **Revenue model mix (FY2025)** [S1, derived %]: There is no subscription revenue. Licensing is an input cost (PTL is a licensee paying royalties—HK$72.4m in FY2025, 14.1% of toy sales), not a revenue stream [S1]. **Value-chain position.** PTL sits between IP owners (Legendary/Toho, Hasbro, Paramount/Viacom historically) and mass retailers. It concentrates on concept, sculpting, packaging, marketing and distribution and contracts finished-goods vendors for manufacturing [S16, playmatestoys.com]. It does not own the underlying IP for its largest lines, which is the structural root of the TMNT loss. **Customer types and end-markets.** Toy customers are large mass-market and specialty retailers, concentrated in the US. In FY2025 three customers each exceeded 10% of group revenue, together contributing HK$420.3m, or 63% of group revenue (derived) [S1]. Property customers are retail, F&B and office tenants at The Toy House, residential tenants at Hillview and industrial tenants in Tuen Mun.

Revenue$0.1B
EmployeesN/A
Market Cap$0.1B
Founded1966
Kowloon, Hong Kong
Photonike

Photonike Capital SA

Premium
Information Technology

Photonike Capital SA is a Brussels-domiciled micro-cap holding company that has repositioned itself three times in sixteen years. It started as a photovoltaic developer, became an industrial turnaround investor, and now pursues a Belgian reinsurance and insurance strategy. It describes itself as a provider of "bespoke risk protection solutions" across industrial, financial and technological risk, and as a manager of turnaround processes. Its stated offering covers credit enhancement, market hedging and alternative-finance structures. Its main live strategic project is obtaining a non-life reinsurance or insurance licence from the National Bank of Belgium (NBB), first applied for in 2020–2021 and still pending in 2026. In practice it is a closely held vehicle: about 80% of shares are held by two holding companies (Homepad SA and FFVentriglia Investment & Finance Ltd). Revenue is sporadic and contract-driven, with about EUR 1.76 million in FY2024 and almost none in earlier years. The shares trade thinly and far below the book values the company has asserted. --- **Company's own description.** Photonike states that it is "a service provider of bespoke risk protection solutions (industrial, financial and technological) as well as a management company of industrial and financial turnaround processes" (Euronext/Cofisem company profile, updated 27 Jan 2025). Aggregator profiles derived from company material add that it "offers tailor made solutions for credit enhancement, market hedging, and alternative finance purposes" (Yahoo Finance; FMP). **Independent characterisation.** On the evidence available, Photonike operates as a personal holding and deal vehicle rather than an operating company with a recurring business. Its activity has been organised around a small number of large, episodic projects: 1. **Industrial turnarounds in Italy (2013 to late 2010s).** It took control of Sandretto, the historic injection-moulding-machine maker at Pont Canavese near Turin, and invested in GBM Holding SpA. It financed these investments with bespoke quasi-equity instruments ("Photonike Special Swap 2017", "Special Convertible 2024", "Special Swap 2020") totalling about EUR 8.18 million, which were later converted to equity (2021 special board report). The Sandretto investment ended badly: trade press reported the company going into liquidation, and Photonike wrote down its Sandretto receivables in the FY2025 accounts (press release, 4 Jul 2026). 2. **Insurance and reinsurance platform (2019 to present).** In 2019 it announced an entry into European life insurance. It took a stake in Nucleus Life AG, a Liechtenstein life insurer, approved by the FMA Liechtenstein in July 2021, placed representatives on its board, and in January 2024 announced control of the holding vehicle Nucleus Holding II ScSP (Luxembourg). In 2020–2021 it applied to the NBB for a non-life reinsurance licence. The 2021–2025 business plan was built around this licence, but it has not been granted as of mid-2026. A 2022 attempt to buy an Italian non-life insurer (referred to in releases as the "Argo"/"AGA Italy" deal) has no publicly confirmed completion. 3. **Contract-based risk-protection services (2024).** In August 2024 it announced a contract worth EUR 1.7 million. This aligns closely with reported FY2024 revenue of EUR 1.76 million, but the link is an inference; the contract counterparty and scope are not disclosed. 4. **Technology adjacency (2023 to present).** It announced the "release of AESG-AI algorithms" in March 2023. In 2025 it invested about EUR 100,000 in an Italian AI developer that will build its risk-assessment software (press release, 30 Jun 2026). **Business and revenue model.**

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded2008
Brussels, Belgium
PanHong

Pan Hong Holdings Group Limited

Premium
Information Technology

Pan Hong Holdings is a small, family-controlled residential developer listed in Singapore, with its operating history concentrated in Huzhou and Hangzhou in Zhejiang Province. Since inception it has delivered more than 660,000 sq m of gross floor area, positioned at owner-occupier buyers in second- and third-tier cities. Its earnings have always been lumpy because revenue is booked only when completed units are handed over. FY2021 was a peak year (revenue RMB1,340.9M; net profit RMB276.7M). Since then the group has shrunk to two largely completed Huzhou-area projects, Run Ze Yuan and Run Hong Yuan, plus one large undeveloped land parcel in Shanwei, Guangdong, bought for RMB717M in 2021. In FY2026, falling Chinese home prices forced RMB239M of inventory write-downs and a net loss of RMB262M. The group then defaulted on a RMB25.5M bank loan and received a going-concern material-uncertainty paragraph from its auditors. Today it is a balance-sheet liquidation-versus-development story, and the shares trade at a deep discount to book value. --- **Company's own description (paraphrased from its corporate profile and FY2024 Annual Report).** Pan Hong describes itself as a Hong Kong-headquartered developer of high-quality residential and commercial properties in China's second- and third-tier cities. It calls itself an early entrant into those lower-tier markets, backed by more than 20 years of management experience. It has established a presence in Hangzhou and Huzhou, and the April 2021 Shanwei land purchase extended it into Guangdong for the first time. The 2015 renaming from "Property" to "Holdings" was explained as reflecting a wish to diversify beyond development into investment holding and other activities. In practice, no material non-property business has emerged. **Business model.** The website and annual reports describe an integrated, in-house development cycle: 1. Site selection and market research. 2. Land acquisition through public tender or auction from local land bureaus. 3. Project conceptualisation, planning and design, using external design institutes. For Shanwei this was Tongji Architectural Design (Group) Co., Ltd., now an arbitration counterparty. 4. Construction by third-party main contractors. 5. Pre-sales, sales and delivery, followed by after-sales service. **Revenue model.** Revenue is close to 100% product-type. It comes from the "sale of properties held for sale" and is recognised on transfer of control at handover, not at pre-sale. Rental income from investment properties (RMB3.1M in FY2026) and interest income are booked in "other income", not revenue. The company has no subscription, licensing or recurring service revenue. *Source: FY2026 results announcement (30 May 2026), Notes 5 and 8.* **Value-chain position.** Pan Hong is a vertically light developer. It owns the land and the development rights, and it controls design briefs, pricing and sales. It outsources design and construction. It holds a small investment-property book (RMB28.3M at 31 March 2026, down from RMB69.6M) and a 16.6% minority FVOCI stake in Zhejiang Gene Stem Cell Biotech Company Limited, carried at RMB20.3M. That stake is a non-core legacy holding. **Customers and end-markets.** Customers are individual PRC homebuyers, mainly owner-occupiers according to management (FY2022 outlook statement). No customer contributed 10% or more of revenue in any reported year. The end-market is PRC new-build residential property in lower-tier cities, currently Huzhou in Zhejiang (selling) and Shanwei in Guangdong (pre-construction). **Independent characterisation.** Today Pan Hong is less a going-concern developer than a single-segment, two-asset vehicle: 1. A run-off book of completed Huzhou-area inventory carried at RMB582.5M. 2. A stalled Shanwei land bank carried at about RMB731.4M as properties under development. These are funded by RMB106.1M of bank and other loans, RMB95.0M of interest-free related-party advances, and about RMB374M of accrued contractor and other payables. The investment case depends on three things: (a) the pace and price at which remaining Huzhou units can be sold; (b) whether Shanwei can be financed and built in a weak third-tier Guangdong market; and (c) the continuing forbearance of contractors, banks and the founding family.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1983
Kowloon, Hong Kong
Paliburg

Paliburg Holdings Limited

Premium
Information Technology

Paliburg Holdings is the intermediate listed holding company in the Lo Yuk Sui family's Century City group. Through four listed entities, it controls one of Hong Kong's largest owner-operated hotel portfolios and a mid-sized luxury and urban-renewal residential development platform. Economically it is a leveraged Hong Kong hospitality-and-property asset holder. Hotels account for roughly half of revenue and essentially all of its positive pre-depreciation segment earnings. Lumpy residential sales, led by Mount Regalia in Kau To, drive cash generation. Mainland China exposure, through Cosmopolitan's Chengdu, Tianjin and Xinjiang projects, is now mainly a source of impairments. The accounting optics are harsh: depreciation on hotels carried at historical cost, plus HIBOR-linked finance costs, have produced five consecutive years of attributable losses. Yet adjusted NAV (hotels at market) is HK$11.65 per share against a share price below HK$0.20, about a 98% discount. The investment case therefore rests on deleveraging through asset recycling, not on earnings. --- ### Company's own description (FY2025 results announcement, 30 Mar 2026; paraphrased) The company describes the Group as four listed entities with diversified interests in properties, hotels, aircraft ownership and leasing, financial assets and other investments. Its significant investments and principal activities are: - property development and investment; - construction and building-related businesses; - hotel ownership; - hotel operation and management; - asset management; - aircraft ownership and leasing; - other investments, including financial assets. The FY2025 announcement says the principal businesses are now concentrated on properties and hotels in Hong Kong. The 1H2026 announcement drops "aircraft ownership and leasing" from the list of group interests, consistent with the aircraft disposal in 2024. ### Group architecture | Layer | Entity | Paliburg's effective interest | Role | |---|---|---|---| | Ultimate listed parent | Century City International Holdings (355.HK) | Controlling shareholder of Paliburg | Holding company | | Intermediate listed holding company | Paliburg Holdings (617.HK) | — | Property development, construction, holding company for Regal | | Listed subsidiary | Regal Hotels International (78.HK) | ~69.3% (FY2022–1H2026) | Hotel operation and management; REIT manager; owner of Regala Skycity Hotel; property projects | | Listed sub-subsidiary | Regal REIT (1881.HK) | Regal holds ~74.9% (≈51.9% look-through, computed) | Owns 4 Regal Hotels and 4 iclub Hotels in Hong Kong after the April 2026 Regal Oriental sale | | 50/50 JV, consolidated | P&R Holdings Limited | 50% direct plus 50% via Regal; a subsidiary in substance | Hong Kong property development; holds the Cosmopolitan stake | | Listed sub-subsidiary | Cosmopolitan International (120.HK) | P&R holds 61.4% of ordinary shares (31 Dec 2025 and 30 Jun 2026), plus convertible preference shares and notes | Mainland China property (Chengdu, Tianjin, Xinjiang) | | Wholly owned | Chatwin Engineering Limited | 100% | Construction and construction management | ### Business and revenue model (FY2025 revenue mix, FY2025 results note 3) | Revenue line (FY2025) | HK$M | % of revenue | Nature | |---|---|---|---| | Hotel operations and management services | 1,843.9 | 48.6 | Service / operating revenue (rooms, F&B, management fees) | | Proceeds from sale of properties | 1,684.7 | 44.4 | Product sale (development inventory) | | Other operations (financing, food products, restaurants, housekeeping) | 91.8 | 2.4 | Mixed services | | Rental income: investment properties | 71.9 | 1.9 | Recurring lease income (mainly We Go MALL) | | Rental income: hotel properties | 42.1 | 1.1 | Recurring lease income (e.g., Campus La Mola, Barcelona) | | Construction and construction-related income | 40.1 | 1.1 | Contracting services | | Estate management fees | 9.2 | 0.2 | Services | | Other (finance lease interest, dividends, financial-asset gains, other rentals) | 8.9 | 0.2 | Investment income | | Total | 3,792.6 | 100.0 | — | There are no subscription or licensing revenue streams of note. Trademark assets (HK$610.2M, mainly the Regal brand) are carried on the balance sheet, but no royalty revenue is separately disclosed. ### Value-chain position, customers and end-markets **Value chain.** Paliburg is vertically integrated across the Hong Kong real-estate value chain: - site assembly, including Land Compulsory Sale proceedings (Castle Peak Road, Hai Tan Street) and Urban Renewal Authority tenders (The Ascent, iclub Mong Kok); - design and development consultancy, plus construction and construction management (Chatwin); - ownership (Regal REIT, P&R, Regal); - operation and management (Regal's hotel management arm); - asset management (Regal Portfolio Management Limited, manager of Regal REIT). **Customer types.** - Hotel guests (leisure and business, including airport and transit demand at Regal Airport and Regala Skycity). - High-net-worth residential buyers (Mount Regalia, Regalia Bay, Casa Regalia). - Mass-market urban buyers (The Queens, The Ascent). - Retail tenants (We Go MALL). - Office and shop buyers in Chengdu and Tianjin. - An overseas hotel lessee (Barcelona). No customer exceeds 10% of revenue (FY2025 note 2). **End-markets:** 1. Hong Kong hotels / tourism. 2. Hong Kong residential development (luxury and urban redevelopment). 3. Hong Kong retail leasing. 4. Mainland China commercial and office property (Sichuan, Tianjin). 5. Minor exposure to European property (Spain; UK and Portugal now exited). ### Independent characterisation Paliburg is best understood as a leveraged NAV vehicle with an earnings problem that is largely accounting-driven but partly real. Three points support this view. **Real operating earnings, masked by depreciation:** The hotel segment generated HK$633.7M of segment results before depreciation in FY2025, but HK$678.0M of depreciation turned that into a HK$44.3M segment loss. The hotels are carried at their 7 May 2012 fair value (or cost) less accumulated depreciation, so book value understates market value by about HK$5.7–6.1bn (adjusted-NAV bridge). **A genuine interest burden:** Finance costs of HK$964.5M in FY2025 exceeded gross profit from hotels and are a real cash cost. Net interest paid was HK$889.8M. **Value realisation depends on disposals:** The FY2025–2026 strategy is explicitly asset recycling: Regal Oriental Hotel, 41 Kingsway, Fabrik, the Chengdu hotel block, and Mount Regalia and The Queens unit sales. The holding-company layering (Century City → Paliburg → Regal → Regal REIT, plus P&R → Cosmopolitan) creates a large minority-interest leakage and a compounded "conglomerate discount".

Revenue$0.5B
EmployeesN/A
Market CapN/A
Founded1984
Causeway Bay, Hong Kong
Oxurion

Oxurion NV

Premium
Information Technology

Oxurion is the shell of a former Belgian ophthalmology biotech. It has been repurposed into a listed vehicle that acquires majority stakes in small European CROs. The heritage is substantial. As ThromboGenics, the company created the pharmacological vitreolysis category with JETREA (ocriplasmin), which was approved in 54 countries. After its last clinical asset, THR-149, failed in November 2023, the company avoided bankruptcy only through a rescue agreement with its convertible-bond investor, Atlas Special Opportunities. It then went through a court-supervised private reorganisation in 2024 and stopped all internal R&D in August 2025. Today its only operating asset is a 72% stake in Axiodis CRO, a Toulouse biometrics and clinical-data-management specialist with about €1.0 million in revenue. Axiodis owns the Exagis CDMS platform. Oxurion is pursuing a buy-and-build strategy: an international CRO LOI (March 2026) and exclusive talks on Eclevar, a MedTech CRO (September 2026). Equity is negative, cash is close to zero, and funding depends entirely on conditional Atlas convertible tranches. --- ### Company's own description (latest filings) The FY2025 Annual Report describes Oxurion as moving from a pure biopharmaceutical R&D model to an integrated European platform of clinical research services. It plans to get there by acquiring majority stakes in promising pharmaceutical subcontractors (CROs). The stated aim is to improve clinical development through clinical data management, biometrics, eClinical technologies (eCRF), regulatory affairs and statistical analysis. The H1 2026 Interim Report describes the group as a "technology-enabled European clinical research group." It combines specialised CRO services, proprietary software (Exagis) and external growth. The client focus is pharmaceutical, biotechnology and medical-device sponsors, with emphasis on clinical data, biometrics and eClinical technologies. Press releases from October 2026 describe the company as building a technology-enabled clinical research and software platform. ### Independent characterisation Oxurion is in practice a micro-cap listed holding company with three characteristics: 1. **One small operating subsidiary (Axiodis CRO).** Axiodis generated about €1.0 million of operating income in calendar 2025 and has been profitable at the net level since inception. 2. **A holding-company cost base larger than the subsidiary's revenue.** This covers listing, reporting, M&A and legacy liabilities. Group G&A was €2.3 million in FY2025 against €0.6 million of consolidated revenue. 3. **A financing structure dominated by one investor, Atlas Special Opportunities II LLC.** Atlas is at once a convertible bondholder, lender, second-ranking pledgee and, intermittently, the largest shareholder. The FY2025 Annual Report states that Atlas is *presumed* to have de facto control under Article 1:14 of the Belgian Code of Companies and Associations (BCCA). ### Business and revenue model | Dimension | Current model (FY2025–H1 2026) | Legacy model (to FY2023) | |---|---|---| | Core activity | Outsourced clinical biometrics: data management, biostatistics, statistical programming, eCRF/CDMS | Ophthalmic drug R&D (DME, AMD, GA); JETREA commercialisation | | Revenue type | Service fees per study mandate (project-based contracts); platform use embedded in services | Product sales (JETREA vials) and royalties | | Product vs service vs licensing mix | ~100% services (FY2025: €555k; H1 2026: €591k) | FY2023: product sales €0.2M, royalties €0.1M (statutory) | | Subscription / SaaS | Not reported separately. Exagis is being productised as a broader eClinical suite (roadmap) | None | | Value-chain position | Tier-3 specialist / functional service provider. Works directly for sponsors and as subcontractor to full-service CROs (e.g., the KYomed INNOV & CEISO partnership) | Drug originator / licensor | | Customers | Pharma, biotech, medtech and academic sponsors. About 10 clients; top 3 ≈ 80% of revenue; largest ≈ 50% (Source: AR FY2025, risk 3.5.2.1) | Ophthalmologists via distributors (Inceptua, Alcon, earlier Novartis) | | End-markets | Clinical development services (drugs and medical devices); new focus offerings in GLP-1, peptides and biosimilars (June 2026) | Retinal disease therapeutics | | Geography | France-based delivery; operational footprint in "more than a dozen countries" (H1 2026 report) | Global | ### Contracting model Axiodis typically signs individual service agreements per trial rather than long-term framework contracts (AR FY2025). It must therefore keep winning new mandates. Revenue visibility is short, and there is no disclosed backlog.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1991
Leuven, Belgium
Origohf.

Origo hf.

Premium
Information Technology

| Field | Detail | |---|---| | Entity originally requested | Origo hf., Nasdaq Iceland, ticker ORIGO (listed as ORIGO.IC in the request list), www.origo.is | | Entity profiled | (a) Skyggnir Eignarhaldsfélag hf. — the same legal entity as Origo hf. (ID no. 530292-2079), renamed 1 Nov 2024; (b) Origo ehf. (ID no. 450723-1690) — the operating IT services company carrying the Origo brand since 1 Nov 2024 | | Former names of legal entity | Nýherji hf. (1992–2018); Origo hf. (Jan/Feb 2018–Oct 2024); Skyggnir Eignarhaldsfélag hf. (from 1 Nov 2024) | | Predecessor lineage | Roots traced to 1899 (office machines); Skrifstofuvélar hf. founded 1946 by Ottó A. Michelsen; IBM sales licence 1949; IBM á Íslandi founded 1967; Nýherji formed 1992 by merger of IBM á Íslandi hf. and Skrifstofuvélar-Sund hf. | | Incorporation jurisdiction | Iceland (hlutafélag / public limited company for Skyggnir; einkahlutafélag / private limited company for Origo ehf.) | | Headquarters (current) | Dalvegur 30A, 201 Kópavogur, Iceland (Skyggnir registered address; Origo signage installed at Dalvegur in 2026) | | Headquarters (historical) | Borgartún 37, 105 Reykjavík (through at least early 2025) | | Stock exchange / ticker | Formerly Nasdaq Iceland main list, ticker ORIGO (Small Cap Iceland segment). Delisted spring 2023. No current listing. | | ISIN / CUSIP | Not publicly verified in sources reviewed; no CUSIP (non-US issuer) | | Fiscal year end | 31 December | | Employees | ~618 (Origo hf. group, data as of FY2022, Simply Wall St); "over 500" (Icelandic Competition Authority Decision 3/2023 describing Origo at takeover); current Origo ehf. headcount not publicly disclosed | | Auditor | KPMG ehf. (re-elected at AGMs in 2021, 2022 and 2023) | | Market capitalization | No current market cap (private). Last reported market cap on delisting approx. ISK 10.3 bn (Simply Wall St, post-capital reduction). Alfa Framtak's takeover was described in Icelandic press as a ~ISK 14 bn transaction | | Controlling shareholder | AF2 slhf. (formerly referred to as Umbreyting II slhf.), private equity fund managed by Alfa Framtak ehf., holding ~65.5% of Skyggnir; Birta lífeyrissjóður (pension fund) ~6.4% (Viðskiptablaðið, 2026) | | Websites | www.origo.is (Origo ehf.); www.skyggnir.is (Skyggnir) | | Current CEO | Origo ehf.: Árni Geir Valgeirsson (from Feb 2026). Skyggnir: Ari Daníelsson | | Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | |---|---|---|---|---|---| | Group employees (approx., headcount) | — | — | — | 618 | 500 | Notes: FY2022 figure from Simply Wall St company profile; FY2023 figure is the "over 500" description in Competition Authority Decision 3/2023 (written early 2023). Wikipedia's older figure of ~750 employees is uncited and likely reflects the pre-2018 Nýherji group including more foreign subsidiaries. Earlier year-end headcounts are not publicly disclosed in sources reviewed. Origo is Iceland's oldest and one of its two or three largest IT services franchises, descended from the country's first IBM distributor and from Nýherji, a listed IT group for roughly a quarter-century. Under the Origo brand it historically combined three businesses: end-user equipment (PCs, Lenovo/Sony/Bose/Canon/Apple hardware and related services), managed services and infrastructure (data centres, outsourcing, cloud, security), and software (own products such as Kjarni HR/payroll, Caren car-rental software, and the Tempo stake, plus SAP and Microsoft ERP integration). Its most valuable creation, Tempo, was sold in 2022 for USD 195 M in cash, triggering a near-ISK 25 bn capital return and a private equity takeover by Alfa Framtak. Since then the group has been dismantled into a holding company (Skyggnir) owning roughly 15 independent IT businesses. Origo ehf. today is a focused Icelandic IT services and knowledge company in managed operations, infrastructure, software, data and AI, while hardware retail (Ofar) has been sold to Nova. --- ### What the company does **Historical listed group (to 2022).** Origo hf. described itself in its last listed years as an IT company delivering digital solutions — application development, systems integration, managed services, technical support, cloud-based payroll and HR systems — primarily to medium and large enterprises in finance, healthcare, public sector, retail and industry, with operations mainly in Iceland and Sweden (company description as reproduced on MFN/Nasdaq Iceland issuer pages, 2023). The consolidated group reported three operating segments (2021 and 2022 annual financial statements): 1. **End-user solutions and related services (Notendabúnaður)** — sale and service of PCs, peripherals, printers, consumer electronics, Apple products (via Eldhaf from 2021), retail stores and web shop; over 40% of group revenue in 2021 and roughly 44% in 2022. 2. **Managed services and infrastructure (Rekstrarþjónusta og innviðir)** — data-centre operations, outsourcing, infrastructure sales (servers, storage, networking), cloud, IT security (Syndis from 2021), HPC (Responsible Compute from 2022), data analytics (Datalab); about 30% of revenue in 2021, 28% in 2022. 3. **Software and related services (Hugbúnaður)** — own software (Kjarni HR/payroll, Caren car-rental, Booking Factory, Reserva, healthcare software later Helix, Tempo as associate), third-party business software (SAP via Applicon in Iceland and Sweden; Microsoft Dynamics/Business Central), web and digital development; about 30% of revenue in 2021, 28% in 2022. **Current structure (from 1 Nov 2024).** **Skyggnir Eignarhaldsfélag hf:** has no operating activity of its own; it is an investment holding company that owns stakes in some 14–16 Icelandic IT operating companies and states its mission as spotting opportunities for progress in Icelandic IT and supporting portfolio companies toward growth or eventual new ownership (Skyggnir website; Vísir, Oct 2024). **Origo ehf:** carries out managed operations (rekstrarþjónusta), infrastructure and software development, and is the largest portfolio company. Management describes it as now a pure IT services and knowledge company (Origo press release on CEO change, Jan 2026). In 2026 it expanded into data/AI via the Maven acquisition and launched an AI-enabled Business Central solution called Bifröst. ### Business and revenue model | Revenue type | Historical group (2021–2022) | Origo ehf. today | |---|---|---| | Product/hardware resale | Largest single stream (end-user segment >40%); low gross margin | Largely exited via Ofar (sold to Nova 2026); some infrastructure resale remains | | Recurring managed services | Significant share of managed services segment | Core | | Professional services/consulting | Software implementation (SAP, Microsoft), security consulting | Core (software, data, AI, Business Central) | | Subscription/SaaS (own IP) | Kjarni, Caren, Booking Factory etc.; own software revenue +24% in 2021 | Largely moved to separate portfolio companies (Corus, Helix, etc.) | | Licensing | Third-party licence resale (SAP, Microsoft, Atlassian) | Continues via partnerships | Gross margin of the group sat at 24.7%–26.8% across FY2020–FY2022, reflecting the large hardware component (FY2021 consolidated financial statements; FY2022 results release). Precise product/service/subscription mix percentages were not publicly disclosed. ### Value chain position and customers Origo occupies the integrator/reseller/service-provider layer of the IT value chain: it buys hardware and software from global vendors (Lenovo, Apple via Eldhaf, IBM historically, SAP, Microsoft, Atlassian), bundles them with its own data-centre capacity, staff and IP, and sells to Icelandic enterprises and public bodies. Customer types include banks and insurers, healthcare institutions (public hospitals, pharmacies via Helix), government and municipalities (e.g., Reykjavík framework agreements for screens and hardware), retailers, travel companies (car rental, hotels) and consumers (through retail). ### Independent characterization Origo was for years a "conglomerate discount" story: a low-margin Icelandic hardware-and-services business (EBITDA margin 7–9%) carrying a minority stake in a high-growth global SaaS company (Tempo) whose value the market struggled to price. The Tempo exit in October 2022 crystallized roughly ISK 22.3 bn of gains, almost all of which was returned to shareholders, and exposed the core business as a mid-sized domestic IT services operator. Alfa Framtak's thesis — articulated in its offer document — was that further restructuring, simplification of governance, property review and a delisting would unlock value. The subsequent break-up (separating hardware retail into Ofar, HR software into Corus, healthcare into Helix, security into Syndis) and the 2026 Ofar sale fit a classic PE "build, carve out, realize" playbook. Cumulative distributions from Skyggnir since the takeover (~ISK 13.4 bn including the proposed 2026 payout) approach the ~ISK 14 bn reported takeover consideration.

RevenueN/A
Employees500
Market CapN/A
FoundedN/A
Kópavogur, Iceland
OptionN.V.

Option N.V.

Premium
Information Technology

Option NV is a Leuven-based micro-cap industrial-IoT company that has come full circle. Once the world's leading supplier of 3G PC data cards (32% global market share and close to €300 million revenue in 2006), the company collapsed under Chinese price competition, was recapitalised and restructured by former Barco CEO Eric Van Zele, rebranded Crescent and run as a small buy-and-build IoT integrator spanning gateways, radio communications, smart lighting and ICT services. After divesting ICT services (2Invision, 2024) and a majority of loss-making Remoticom (2025), the group has narrowed to three units — Option (CloudGate secure cellular IoT gateways and sensors), SAIT (radio-communication integration) and Innolumis (smart LED public lighting) — and readopted the Option name. Group revenue is about €9–10 million, EBITDA hovers around breakeven, equity is thin and funding depends heavily on the reference shareholder. The equity story now rests on the 5G CloudGate NXS/Nexus launch, US distribution through GetWireless, and nascent defence (Sol.One) and energy-management niches. --- ### What the company does Option NV designs, sources and sells connectivity hardware and integration services for the Internet of Things, and operates two adjacent businesses in professional radio communications and smart public lighting. Following the August 2025 sale of 51% of Remoticom Holding BV, the group reports through three operating entities (H1 2026 results release, 17 Sep 2026): 1. **Option (IoT / CloudGate)** — the historic core. Option develops the CloudGate family of programmable, secure cellular IoT gateways (4G/LTE, LoRa and, with the new NXS/Nexus generation, 5G) and associated sensors (parking, motion, leak detection, energy metering). Revenue H1 2026: €1,836k (39% of group). 2. **SAIT** — radio-communication and integration services (historically part of Zenitel's Belgian activities, per the FY2022 chairman's comments referring to "Zenitel/Sait"). Revenue H1 2026: €1,334k (28%). 3. **Innolumis** — smart LED public lighting fixtures and controls, historically sold mainly in the Dutch home market, with export projects (e.g., Morocco, Croatia, Eastern Europe). Revenue H1 2026: €1,528k (33%). A small group-cost centre (€307k H1 2026) sits above these units and covers listed-company costs that management itself has described as "still far too high" (29 May 2026 release). ### Company's own description (paraphrased, latest disclosures) In its FY2025 results release (29 April 2026), management framed 2025 as the year the group decided to concentrate on its core competence in connectivity, presenting Option as recognised for technological excellence in IoT gateways and stating an ambition to convert that technical leadership into international market leadership. The 21 January 2026 release described the renaming as a way to capitalise on Option's historical reputation for leadership and technological excellence in international markets. The September 2025 transformation release set out three "pillars": (1) world-class IoT connectivity via a rejuvenated, fully certified CloudGate line with high cybersecurity; (2) defence, specifically RF technologies for drones and land/aerial vehicles; and (3) artificial intelligence as a software layer for IoT systems. ### Business and revenue model | Revenue model component | Description | Indicative weight (H1 2026) | |---|---|---| | Hardware product sales | CloudGate gateways, sensors, lighting fixtures, controllers | Majority of Option and Innolumis revenue (Option + Innolumis = 72% of group revenue) | | Project / integration services | SAIT radio-communication integration projects; Innolumis lighting projects; Option engineering (e.g., Sol.One) | SAIT 28%, plus project elements in other units | | Software / platform | CloudGate Universe (device management portal referenced on website as "cg universe"); historically a leisure SaaS platform (sold with 2Invision) | Not separately disclosed | | Licensing / recurring | Not separately disclosed; no recurring-revenue metric published | Not publicly disclosed | The model is predominantly transactional hardware and project revenue, with no disclosed recurring-revenue base — a key difference from larger IoT peers such as Digi International, where annualised recurring revenue is about 35% of revenue (Digi FY2025 release). ### Value-chain position Option is a fabless/asset-light designer: it designs gateways and sensors and outsources manufacturing to assembly partners. FY2025 results disclosed that a reorganisation at its assembly partner caused roughly €700k of orders to slip out of 2025. CloudGate Nexus production was started in the United States in September 2026 (contract manufacturer not disclosed). Distribution runs through channel partners (GetWireless in the US, whose customers include Verizon Wireless) and system integrators/OEMs. Innolumis similarly designs and assembles/sources luminaires for municipal customers. SAIT sits downstream as an integrator. ### Customer types and end-markets | End-market | Unit | Customer types | Evidence | |---|---|---|---| | Industrial / enterprise IoT connectivity | Option | OEMs, system integrators, carriers' enterprise channels (US via GetWireless/Verizon) | 29 May 2026 release | | Internet service providers / business continuity | Option | ISPs bundling failover connectivity | ViaLinx.io partnership, 19 Jun 2026 | | Energy management systems | Option (EMS division) | Industrial and public-sector asset owners | EMS division launch, 13 Feb 2026 | | Defence / security | Option | Drone/UAS makers (Sol.One) | Sol.One MoU Oct 2025, frame agreement Nov 2025, first contract Jun 2026 | | Professional radio communications | SAIT | Industrial, public, transport operators (specific customers not disclosed) | Segment disclosures | | Smart city / public lighting | Innolumis | Municipalities, public-lighting operators (NL, Morocco, Croatia, Eastern Europe) | FY2024 & H1 2025 releases | ### Independent characterisation Option today is best described as a sub-€10-million, three-legged IoT and lighting hardware business with a single potentially scalable asset (the CloudGate platform), wrapped in a listed shell carrying the cost and governance burden of a much larger company. Its financial history since 2018 is one of serial portfolio reshaping (acquisitions of Remoticom; divestitures of Uest, Maro, 2Invision and 51% of Remoticom), recurring net losses, impairments, and repeated recapitalisations led by the reference shareholder. The investment case is binary in character: if CloudGate NXS achieves the volumes implied by the initial 10,000-unit US order (about USD 5 million, roughly equal to half of 2025 group revenue), the group could double the Option unit and reach sustainable profitability; if not, continued dependence on related-party funding and further dilution are likely.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1986
Heverlee, Belgium
Onelogix

Onelogix

Premium
Information Technology

OneLogix is a privately owned Southern African logistics group built by acquiring and incubating specialised, owner-managed transport businesses that each lead a defined niche. Its portfolio covers new-vehicle and commercial-vehicle delivery and storage (OneLogix VDS, OneLogix TruckLogix), abnormal-load and project cargo (OneLogix Mega, formerly Projex), bulk liquids and cryogenic gases (OneLogix UB, OneLogix Cryogas), refrigerated and agricultural freight (OneLogix Jackson, OneLogix Buffelshoek), cross-border general freight (OneLogix Linehaul), and port-centric services: clearing and forwarding, intermodal, warehousing, vehicle fitment, panel repair and 4PL. A Namibian heavy-haul and mining logistics business (OneLogix HCL) has since been added. The strategic anchor is the Umlaas Road logistics hub between Durban and Pietermaritzburg, which links Durban port to inland vehicle storage, preparation and distribution. The group reported R3.07bn revenue and R411m EBITDA in its last published year (FY2022). It was taken private by management in 2023 and now markets itself as a single integrated logistics partner across roughly 15 Southern and East African countries. --- **What the company does.** OneLogix provides asset-backed road transport and related logistics services in specialised niches where equipment, compliance and know-how create barriers that general hauliers find hard to cross. Its services are: - Car-carrier transport of passenger and light commercial vehicles for OEMs, importers, dealers, fleets and private customers, combined with bonded and duty-paid storage, pre-delivery inspection, preservation, Datadot application and port operations. - Delivery of commercial vehicles over 3.5 tons, either self-driven or "off-wheel" on carriers. - Abnormal and out-of-gauge project cargo of 100+ tons, plus assembly of mining, construction and agricultural equipment. - Hazardous and non-hazardous bulk liquids (acids, solvents, food-grade products) and cryogenic gases at temperatures down to −196°C. - Refrigerated long-distance freight between −25°C and +25°C. - Bulk and breakbulk agricultural, mining and industrial freight. - Cross-border general freight into and out of South Africa. - Clearing and forwarding, intermodal container logistics, warehousing, vehicle fitment and testing, and panel beating. **Business model.** Historically the group used a decentralised "federation" model. Head office supplied capital, finance, payroll, IT, HR, SHEQ, risk and strategy, while founder-managers and their teams ran each business, often keeping minority stakes. Examples include the 26% retained by Jacques du Randt in Jackson and the 16% retained in Buffelshoek at the 2015 acquisition, and the material non-controlling interests that took 25.5m of FY2022 profit. Business Day columnist Chris Gilmour (2020) described this as a formula for acquiring businesses while keeping their entrepreneurial talent. Since delisting, the website shows a shift toward a single branded, integrated "one partner" offering under unified SHEQ, technology and customer interfaces. **Revenue model.** Revenue is almost entirely service-based (FY2022 audited results): *Source: OneLogix FY2022 audited summary results, supplementary information.* The group earns no subscription or licensing revenue. Contracts are per-trip, per-tonne or per-vehicle tariffs plus contracted storage and handling fees. A meaningful part of revenue is fuel-cost pass-through: about R110m of extra recovery in FY2019 and about R190m in FY2022 came from higher average fuel prices. Revenue growth can therefore overstate volume growth. **Value-chain position.** OneLogix sits mainly in the asset-based execution layer (4PL/3PL road transport). It is increasingly adding port-adjacent services (clearing, intermodal, CAF fitment, bonded storage) and a 4PL offering (OneLogix SCS), which moves it up the chain toward integrated supply-chain management. **Customer types.** Vehicle OEMs and importers, motor dealers, rental and fleet operators, chemical and petrochemical producers, industrial gas companies, food and FMCG producers, agricultural co-operatives and input suppliers, mining houses, construction and renewable-energy contractors, defence and marine customers (OneLogix HCL), and private individuals (VDS private vehicle moves). The website describes its customers as "blue-chip organisations". Named customers are not publicly disclosed in the current materials. A 2012 profile cited Eskom, Sasol and Barloworld Logistics as Projex-era clients. **End-markets.** Automotive (imports, exports and domestic distribution), chemicals and petrochemicals, industrial gases, agriculture and food, mining and minerals, construction and energy projects, FMCG, and cross-border trade to SADC and East Africa. **Company's own description (paraphrased from FY2022 results and the current website).** In FY2022 the group called itself a niche logistics group whose businesses each hold strong positions in their markets with resilient management teams and loyal customer bases. Its current website describes OneLogix as Southern Africa's integrated logistics and supply-chain solutions provider, which brought specialised divisions under one system, standard and point of accountability to remove the handover risk of fragmented logistics. **Independent characterisation.** OneLogix is a mid-sized, asset-intensive, owner-managed road logistics roll-up. Its moat comes from specialised fleets (car carriers, cryogenic tankers, abnormal-load trailers), regulatory accreditation (SQAS, RTMS, ISO 39001, PPECB, bonded-carrier status, International Cyanide Management Code), B-BBEE Level 1 status, and one hard infrastructure asset: the Umlaas Road hub, held through long-dated sale-and-leasebacks. Its economics are cyclical, especially in the automotive storage component, and lease-heavy. As a listed company it produced high EBITDA margins (13–15%) but thin net margins (1–3% in FY2020–FY2022).

Revenue$0.2B
Employees1,980
Market CapN/A
Founded1998
United States, North America
Oceana

Oceana Group Limited

Premium
Information Technology

Oceana Group is Africa's largest fishing company and one of South Africa's oldest listed food businesses. It is a vertically integrated harvester, processor and marketer of marine protein. The group combines three businesses: **A consumer franchise:** Lucky Star is the dominant canned-pilchard brand in Southern Africa and is expanding into canned meat and other shelf-stable foods. **A hard-currency commodity business:** Fishmeal and fish oil are produced in South Africa and, through Daybrook Fisheries, in Louisiana, USA. **An export-oriented wild-catch business:** This covers hake, horse mackerel, squid and rock lobster, sold into European and African markets. The portfolio spreads risk across species, geographies and currencies. Rand-priced, defensive canned-food demand is offset by US dollar and euro export earnings, which act as a natural currency hedge. The group's resilience depends on biological resources it does not control: quotas, catch rates and global supply shocks such as Peruvian anchovy seasons. It also depends on South Africa's fishing-rights and transformation framework, in which Oceana holds Level 1 B-BBEE status. --- ### Company's own description Across its integrated reports and handbook entries, Oceana describes itself as a diversified international fish and food company. It says it operates across the full value chain: catching or procuring, processing, distributing and selling. It positions itself as Africa's largest fishing company, with a history of more than a century (Profile Handbook 2026, company-supplied text). Its stated "principal market" is the lower-end consumer, who favours canned fish and horse mackerel as affordable protein (as reported by Just Food, December 2025, citing company materials). ### What the company does Oceana runs four reporting segments (FY2025 revenue share in brackets; computed): 1. **Lucky Star foods (48.7%).** - Branded canned pilchards, sold in South Africa and exported regionally and further afield. - Increasingly also canned meat, canned vegetables and new categories such as noodles. - Raw material comes from local pilchard landings and imported frozen sardine/pilchard (Pacific, Morocco and others), canned in South African facilities. Finished goods are also procured. 2. **Fishmeal and fish oil — Africa (8.9%).** - Reduction of industrial fish (anchovy, red-eye herring) and cannery pilchard trimmings into fishmeal and fish oil. - Done at two West Coast plants and sold mainly in US dollars to aquafeed, animal-feed and oil-refining customers. 3. **Fishmeal and fish oil — USA (23.7%).** - Daybrook Fisheries, Louisiana, processes Gulf menhaden. - The fish are landed by fishing partner Westbank Fishing LLC, in which Oceana holds 25% via Daybrook. - Daybrook sells fishmeal and fish oil in US dollars. 4. **Wild caught seafood (18.7%).** - Deep-sea hake (frozen, exported mainly to Europe). - Midwater-trawl horse mackerel, caught in Namibia and South Africa and sold largely into African markets. - Squid (Europe) and West Coast and South Coast rock lobster. ### Business and revenue model Oceana's revenue is almost entirely product revenue. There is no material service, subscription or licensing revenue since the April 2023 sale of the CCS cold-storage business, which was its only services business. The mix splits into: - **Branded consumer goods with pricing power, but bounded by affordability.** Lucky Star is managed deliberately for volume and affordability rather than maximum margin. In FY2023 the company did not pass through the full input-cost inflation. **Globally priced commodities:** Fishmeal and fish oil are priced off Peruvian anchovy supply, aquaculture demand and omega-3 demand. **Export seafood priced in EUR/USD:** Hake, squid and lobster go to Europe; horse mackerel goes to Africa. ### Value-chain position Oceana holds harvesting rights and operates vessels in hake, horse mackerel, squid, lobster, pilchard and industrial fish. It processes on land in canneries and reduction plants, and owns brands and distribution (Lucky Star). For Daybrook it relies on a contracted fishing partner (Westbank) rather than owning the fleet outright. For Lucky Star it relies heavily on imported frozen fish when local quotas are insufficient. Local pilchards were only 18.4% of raw fish canned in FY2023 and 22.5% in FY2024 (SENS FY2023, FY2024). ### Customer types and end-markets **Lucky Star:** South African grocery retail and wholesale, including retailer-brand production of canned meat (H1 FY2026 presentation). Also neighbouring Southern African countries, West Africa (entered in FY2025, including Ghana, per CEO interview with EWN, 25 November 2025), selected European markets (re-entry noted in H1 FY2026), and school-nutrition programmes. **Fishmeal and fish oil:** Aquafeed (notably shrimp and salmon), pet food, animal feed, and omega-3 refining (including Chinese refining demand), per the H1 FY2026 presentation's market outlook. **Hake and squid:** European importers and processors. **Horse mackerel:** African markets where it is a low-cost protein. **Lobster:** Export markets (destinations not disclosed in the sources reviewed). ### Independent characterisation Oceana is best understood as a cash-generative but cyclical protein conglomerate. The defensive core (Lucky Star) is paired with a high-beta commodity earner (Daybrook), whose contribution swung from 72.2% of group operating profit in FY2024 to about 43% in FY2025 (computed: R537m of R1,253m). Group earnings are therefore driven less by management execution than by: - Peruvian anchovy quotas and the resulting fish-oil price cycle; - Gulf menhaden landings and oil yields; - South African and Namibian TAC decisions; - global frozen-sardine availability; - the USD/ZAR exchange rate. Management's controllable levers are fleet reliability, plant efficiency, working-capital discipline and product-range extension. These were visibly improved over FY2023–H1 FY2026: hake sea-days rose, cannery yields improved and net debt fell sharply.

Revenue$0.6B
Employees3,637
Market CapN/A
Founded1918
United States, North America
NyxoahS.A.

Nyxoah S.A.

Premium
Information Technology

| Field | Detail | |---|---| | Legal name | Nyxoah SA (société anonyme / naamloze vennootschap under Belgian law) | | Former names | None publicly disclosed | | Founded | 2009 (founded by Robert Taub, current Chairman) | | Incorporation jurisdiction | Belgium | | Registered office / HQ | Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (per SEC Form 6-K cover, June 2026) | | Primary listing | Euronext Brussels — NYXH (since September 2020) | | Secondary listing | Nasdaq Global Market — NYXH (since July 2021) | | Other trading venues | Stuttgart (5YI), among other German venues — unofficial secondary trading | | ISIN | BE0974358906 | | CUSIP | Not publicly disclosed in sources reviewed (Nasdaq line trades as ordinary shares, not ADSs) | | SEC filer status | Foreign private issuer; files Form 20-F (annual) and Form 6-K (current/quarterly); CIK 0001857190 | | Fiscal year end | 31 December | | Employees | not publicly disclosed in sources reviewed. Directionally, the U.S. sales organisation grew from 25 to 40 field representatives in Q1 2026, with a plan to reach 55 territories in H2 2026 | | Auditor | Not re-verified for FY2025 in this research cycle (historically a Big Four firm's Belgian practice; confirm against the 20-F) | | Market capitalisation (current) | About USD 98M at USD 0.96 intraday on 19 October 2026, after a ~13% fall on the guidance cut (Stock Titan); about USD 113M at the USD 1.11 close on 16 October 2026 (Yahoo Finance) | | Shares outstanding | 101,840,217 as of 25 August 2026, per a company share-capital notice cited by a third-party tracker; later convertible-bond share settlements may have added to this | | Website | www.nyxoah.com | | Investor relations | IR@nyxoah.com — Rémi Renard, Head of IR & Corporate Communication | | CEO | Liam Kelly (effective 1 October 2026; former Chairman, President & CEO of Teleflex) | | Interim CFO | Loïc Moreau (President International; interim CFO from 2 October 2026) | | Chairman | Robert Taub (founder) | The entity profiled is the same listed company identified in the request: Nyxoah SA, the Belgian parent of the Nyxoah group. The listing details supplied are current. No name change or listing migration has occurred. Since July 2021 the company has been dual-listed on Euronext Brussels and the Nasdaq Global Market, both under the ticker NYXH. Nyxoah is a Belgian medical technology company that has built a single, differentiated therapy platform for obstructive sleep apnea (OSA). Its Genio system is a hypoglossal nerve stimulation (HGNS) implant that stimulates both branches of the hypoglossal nerve. The implant is small, leadless and battery-free, and it is powered each night by an external activation chip worn on a disposable adhesive patch under the chin. Genio has carried a CE Mark since 2019 and won U.S. FDA PMA approval on 8 August 2025. Nyxoah is therefore the first credible U.S. challenger to Inspire Medical Systems, which has held an effective monopoly in HGNS. The company's thesis rests on four features: bilateral stimulation, full-body MRI compatibility, no implanted battery that must be replaced surgically, and a potential label extension to complete concentric collapse (CCC) patients, who are contraindicated for Inspire. It remains loss-making and dependent on capital markets. Its near-term value depends on how fast U.S. adoption ramps, on reimbursement clarity, and on patent litigation with Inspire. --- ### Company's own description In its FY2025 Form 20-F, Nyxoah describes itself as a medical technology company focused on developing and commercialising innovative OSA treatments. It calls its lead solution, Genio, a CE-Marked, patient-centric, minimally invasive, next-generation hypoglossal neurostimulation therapy for moderate to severe OSA. The company frames OSA as the world's most common sleep-disordered breathing condition, associated with higher mortality risk and comorbidities such as cardiovascular disease, depression and stroke. It describes Genio as a first-of-its-kind HGNS device that uses bilateral stimulation to keep the airway open during sleep. (Source: Form 20-F, FY2025.) The company began generating revenue from Genio sales in Europe in July 2020. It reports that its main sources of capital to date have been private placements, public equity offerings, debt financing and product revenue. (Source: Form 20-F, FY2025.) ### Independent characterisation | Revenue component | Nature | Disclosure status | |---|---|---| | Implantable stimulator + surgical kit | One-time capital-like product sale per procedure, billed to hospital / ambulatory surgery centre (ASC) | Not separately disclosed | | External activation chip / charging unit | One-time device sale bundled with the system | Not separately disclosed | | Disposable adhesive patches | Recurring consumable, recognised over the delivery period (deferred revenue) | Partially visible via deferred revenue: €1.0M deferred in FY2025, €0.3M in Q1 2026 | | Services / subscription / licensing | None material | Not applicable | Nyxoah is a single-product, single-indication, implant-plus-disposables business. Its economics resemble an active implantable neuromodulation company, such as a spinal cord stimulation or cochlear implant maker, with one important difference: Genio has a recurring consumables component. Each patient needs a steady supply of disposable adhesive patches to attach the external activation chip. That creates a modest annuity tail. Under IFRS 15 this tail forces revenue deferral, because patches delivered over time are recognised over time. **Revenue model mix (analyst characterisation; not segment-disclosed):** **Value-chain position:** Nyxoah designs the device and controls final assembly and quality in Mont-Saint-Guibert, Belgium. In January 2023 it entered a collaboration with Cochlear Limited to transfer assets and support the set-up of a U.S. production line (Source: Q3 2025 interim report, 6-K/A). Distribution is direct in the U.S., Germany and other core European markets, and goes through distributors in the Middle East. **Customer types:** The paying customers are hospitals and ASCs, which buy the system and bill payers. The clinical decision-makers are ENT/sleep surgeons, with referral flowing from sleep physicians. Reimbursement comes from Medicare (U.S. facility C-codes C8011–C8013 established February 2026), commercial insurers (CPT codes for HGNS implantation, with prior authorisation required) and European statutory systems (Germany's DRG system, the UK NHS Specialised Services Devices Programme, and others). **End market:** Moderate-to-severe OSA in adults who fail or cannot tolerate positive airway pressure (PAP/CPAP) therapy. This is the "second-line" OSA market that Inspire created and still dominates. ### The clinical/regulatory foundation | Study | Purpose | Key outcome | Status | |---|---|---|---| | BLAST OSA | European CE Mark study | Supported CE Mark (2019) | Completed | | BETTER SLEEP | Bilateral stimulation incl. CCC patients (Australia/Europe) | Supported CE Mark extension to CCC patients | Completed | | DREAM (U.S. IDE pivotal) | FDA PMA support | Met primary endpoints (announced 19 March 2024); published in *Journal of Clinical Sleep Medicine*. Labelling reflects efficacy in both supine and non-supine positions (per Q4 2025 earnings call) | Completed; PMA approved 8 August 2025 | | ACCCESS (U.S. pivotal, CCC) | U.S. label expansion to CCC patients; FDA Breakthrough Device Designation | 12-month AHI responder rate 77.2% (Sher criteria, p<0.001); ODI responder rate 87.7% (p<0.001); zero device-related serious adverse events; n=47 implanted | Topline 2 September 2026; full data at ISSS 15–16 October 2026; PMA supplement submitted (disclosed 19 October 2026) | | BREATHE (U.S. post-approval study) | FDA-mandated PAS | First patient implanted 7 September 2026 | Enrolling | | European PMCF (NCT04031040) | Long-term post-market follow-up | Registry primary completion estimate 30 October 2026 | Ongoing | The U.S. label covers moderate-to-severe OSA with an apnea-hypopnea index (AHI) of 15 to 65 (FDA approval, 8 August 2025). The treatment of CCC patients currently appears in the warnings section of the U.S. indications for use (company boilerplate, October 2026).

Revenue$0.0B
EmployeesN/A
Market Cap$0.1B
Founded2009
Mont-Saint-Guibert, Belgium
Nutritional

Nutritional Holdings Limited

Premium
Information Technology

Nutritional Holdings Limited is a small South African investment holding company. It was built around Nutritional Foods (Pty) Ltd, a fortified staple dry-food maker in Klerksdorp whose business traces back to 1947. The group sold maize-based porridges, soya mince, beverages and instant meals to institutional and mass-market customers. From 2016 it tried several diversifications: Kairos Nutrition (infant feeding), Venlai Strategic Solutions (renewable energy and security distribution), and from late 2019 cannabis through Ukusekela Holdings. Ukusekela's cannabis-extract "Ultimate Immune Booster" drove the group's first reported profit in seven years (FY2020), alongside very large announced export supply contracts. That pivot then ran into a series of governance failures: - a qualified audit opinion; - loss of control over the food subsidiary; - results that were restated; - frequent changes of finance directors; - liquidation proceedings brought by a former director. These events led to JSE suspension in May 2021 and termination of the listing in December 2022. Today the company is an unlisted entity whose operating status has not been disclosed. --- **Company's own description.** Before it was suspended, the company described itself in its listing particulars as an investment holding company. Its interests covered the manufacture, marketing and distribution of staple dry foods, cannabis infusions, oils, extracts and related edibles [S5]. Earlier handbook entries described a mass-market food business with recognised brands in the LSM 3–6 consumer segment, diversified by product, geography and urban/rural spread. The company argued that the capital cost of replicating its factory was a barrier to entry [S1]. The last reviewed interim report (H1 FY2021) organised the group into two operating activities: Foods and Cannabis [S6]. **Independent characterisation.** In practice the group was a single-factory food processor whose revenue never exceeded about R43 million a year in the five audited years from FY2016 to FY2020 [S1]. Losses before FY2020 were funded mainly by shareholder loans [S6]. The cannabis business started as a management agreement under which Nutritional Holdings managed Ukusekela Holdings for its own profit and loss while the acquisition was pending [S7]. The acquisition took effect on 1 October 2020 [S6]. Revenue from this business was reported as "Services" in the segment note [S6]. **Business and revenue model.**

Revenue$0.0B
Employees102
Market CapN/A
Founded2004
United States, North America
NUTEX

NUTEX Investments Public Limited Company

Premium
Information Technology

NUTEX is a former Hungarian pharmaceutical research company — originally HUMET, developer of the humic/fulvic-acid trace-element preparation HUMET-R — that has transformed over the past decade into a cash-rich, operationally dormant listed investment holding company. It no longer manufactures or sells products; its sole operating revenue (HUF 0.45 M in FY2025) comes from leasing fully amortised intangible assets to a single Hungarian counterparty. Its economic value lies in a balance sheet of roughly HUF 6.1 bn (30 June 2026) composed almost entirely of cash (EUR, USD and HUF deposits), liquid Budapest-listed equities (dominated by OTP Bank), Hungarian government securities and units of an Erste euro real-estate fund, with no debt. Hungarian financial media describe it as an "empty" listed shell that could serve as a reverse-listing vehicle. Management's stated strategy is acquisitive, and since 2025 it has built a holding/acquisition subsidiary chain, but no acquisition has yet closed. The shares trade at roughly one-third of book value. --- ### The company's own description (2025 Annual Report and H1 2026 Report) In its FY2025 consolidated management report, NUTEX describes itself as having operated throughout 2025 essentially as a company managing its own assets, whose activity consists of managing and coordinating its assets and investments. It continued to lease out its intangible assets, invested part of its cash in liquid securities (mainly Budapest-listed shares and Hungarian government securities), and held significant EUR and USD bank deposits plus investment units of the Erste Open-ended Euro Real Estate Investment Fund. The company states that it repaid its former long-term debt in full in earlier years and that, under its acquisition strategy, it examined new acquisition opportunities during the year, none of which had been completed. The stated corporate purpose (H1 2026 Report, Note 1) is to manage the group's assets, ensure the sustainability of group members and increase shareholder value. The strategy includes shaping the investment portfolio through new company formation or acquisitions, and possibly reorganising, selling or realising existing holdings; promoting geographic expansion of investments; and exploiting intangible assets through leasing. The company notes that its investments were historically concentrated on human-health-related businesses, but that other types of investment may also feature in its strategy. ### Independent characterisation | Business-model dimension | Assessment | |---|---| | Revenue model | Licensing/leasing of intangible assets (100% of revenue; one Hungarian counterparty). No product, service or subscription revenue | | Economic earnings model | Investment income: fair-value gains on listed equities, dividends, interest; FX gains/losses | | Value-chain position | None in an operating sense; capital allocator / holding company | | Customer types | One related or unrelated licensee (identity not disclosed) | | End-markets | Effectively Hungarian capital markets (OTP, MOL, Richter shares; Hungarian government bonds) and euro-area real estate (via Erste fund) | | Revenue mix (FY2025) | Licensing 100%; product 0%; service 0%; subscription 0% | NUTEX is, in substance, a listed cash-and-securities shell with an acquisition mandate. Its income statement is driven almost entirely by mark-to-market movements on its securities portfolio (above all OTP Bank shares), dividends received, and foreign-exchange revaluation of its EUR/USD deposits. Operating costs (HUF 108.9 M SG&A in FY2025) are dominated by non-cash IFRS 2 share-based payment charges linked to its Employee Share Ownership Programme (MRP), rather than by an operating business. **Interpretive note:** Because the revenue line is immaterial (HUF 0.45 M), conventional revenue-based metrics (margins, EV/Sales, revenue CAGR) are not meaningful. The appropriate analytical lens is that of a closed-end holding company: net asset value (NAV), the composition and risk of the asset base, cost drag on NAV, governance and capital-allocation discipline, and the probability and quality of a transformative acquisition.

RevenueN/A
Employees1
Market CapN/A
Founded1996
United States, North America
NinetyOne

Ninety One Group

Premium
Information Technology

Ninety One is an independent, active, emerging-market-rooted global investment manager. It was founded in South Africa in 1991 as Investec Asset Management and demerged from Investec in March 2020. It manages £181.4bn (30 September 2026) for institutional asset owners (pension funds, sovereign wealth funds, central banks, insurers) and advisor channels (wealth managers, private banks, IFAs) across five client regions. Africa is the largest region (47% of AUM at March 2026), followed by Asia-Pacific/Middle East (19%). The firm's differentiation rests on specialist active capabilities in emerging-market equity and debt, quality and "4Factor" equities, natural resources and gold, and multi-asset, together with a dominant South African franchise that was reinforced in February 2026 by the acquisition of Sanlam Investment Management. Employees own about 29.4% of the firm, so it is staff-controlled in practice. It runs a capital-light, debt-free model with a 32% adjusted operating margin and pays out roughly three-quarters of adjusted earnings. Management describes the stance as moving from "defensive" to "risk-on" growth within strategic tramlines. --- ### Company's own description (IAR 2026) Ninety One describes itself as "an active investment manager" that invests on behalf of clients "to achieve their long-term investment objectives". Its stated purpose is "Investing for a better tomorrow", structured around Better firm, Better investing and Better world. The firm calls itself client-focused, people-centric, capital-light, and technology- and AI-enabled. It says it develops investment capabilities organically, operates globally in both the institutional and advisor space, and grows in line with structural medium- to long-term demand and competitive performance (IAR 2026, Our Business Model; Our Strategy). ### Business model and revenue model | Revenue line (FY2026, £m) | Amount | % of net revenue | |---|---|---| | Management fees | 617.3 | 94.9 | | Performance fees | 32.9 | 5.1 | | Net revenue | 650.2 | 100.0 | | Other income (in adjusted operating revenue) | 9.1 | n/m | | Adjusted operating revenue | 659.3 | n/m | Ninety One earns almost all its revenue from ad valorem management fees, charged as a percentage of AUM. In FY2026 management fees were £617.3m, or 94.9% of net revenue of £650.2m. The remainder came from performance fees on a limited set of strategies (£32.9m, 5.1%). A further £9.1m of other income (operating interest, FX and investment gains, associates) is counted in adjusted operating revenue of £659.3m. The model has no product, subscription or licensing component in the conventional sense. It is a pure service and recurring-fee business. Revenue therefore depends on three things: average AUM (£151.8bn in FY2026), the average management fee rate (40.7bps in FY2026, down from 44.0bps) and performance fees. Source: IAR 2026, Financial Review. ### Value-chain position Ninety One sits in the manufacturing (investment management) layer of the asset-management value chain. It also has a distribution and administration presence in South Africa through the South African fund platform for independent financial advisors, which hosts both Ninety One and third-party funds (£17.5bn AUA/AUM at March 2026), and through Ninety One Assurance, an investment-linked insurance entity used for life-wrapped pooled products. Fund administration, middle office and parts of operations are outsourced to service providers. State Street is the long-standing outsourcer (a multi-decade relationship), and the State Street Alpha platform and Charles River went live in FY2026 (IAR 2026). ### Customer types and end-markets **Institutional:** public and private pension funds, sovereign wealth funds, central banks, insurers, corporates, endowments. **Advisor:** wealth managers, private and retail banks, IFAs, plus the SA fund platform. **Strategic partner flows:** Sanlam, under a 15-year agreement, as primary active manager for Sanlam's single-managed local and global products, with preferred access to Sanlam's SA distribution. **End-markets by client region (AUM, 31 Mar 2026):** Africa £80.4bn (47%), Asia Pacific incl. Middle East £31.8bn (19%), UK £23.7bn (14%), Americas £18.0bn (10%), Europe £17.9bn (10%). ### Independent characterisation Ninety One is best understood as a mid-sized, emerging-markets-specialist active manager with a structurally advantaged South African home franchise. Its economics resemble UK-listed specialist active peers such as Ashmore and Jupiter. Its client base, however, is more institutional and more geographically diverse, and its South African business, which is about 47% of AUM and now enlarged by Sanlam Investment Management, behaves like an annuity anchor. Its two main exposures are: 1. Global allocator sentiment toward emerging markets and active management, which drove net outflows of £10.6bn in FY2023, £9.4bn in FY2024 and £4.9bn in FY2025, then inflows of £2.8bn in FY2026. 2. Fee-rate dilution from mix and from the lower-fee Sanlam book. The firm is debt-free and lightly capitalised (capital coverage of 241% of requirement), and governance is aligned through employee ownership.

Revenue$857.8B
Employees1,346
Market CapN/A
Founded1991
United States, North America
NewtreeS.A.

Newtree S.A.

Premium
Information Technology

Newtree Impact is one of the very few listed, retail-accessible vehicles in Europe that specialise in early-growth agri-food technology. It is the former Belgian functional-chocolate company NewTree, converted into an evergreen holding that takes minority stakes of roughly €0.3M to €2.5M in Series A to growth-stage companies and in specialist funds. Its themes are food-tech (alternative proteins, precision fermentation, alternative fats and cocoa), agri-tech (precision agriculture, pollination) and food loss. With about €25M of NAV, €17.5M deployed into 25 lines, no debt and about €10.8M of cash at end-2025, it is still sub-scale. Its distinguishing features are its "société à mission" status (the company says it was the first Belgian financial company to adopt it), an independent Mission Committee, IRIS+-based impact reporting and a model of citizen "crowdlisting" alongside institutional anchors (Wallonie Entreprendre, SFPIM). The investment case rests on portfolio maturation toward profitability and exits, against a backdrop of NAV per share that has slipped since 2023 and a very illiquid share. --- ### What the company does Newtree SA is an investment holding company. It raises equity from private investors, family offices, institutions and the public, and invests that capital as a minority shareholder in private companies and venture funds working on the agri-food system. Its stated purpose is to fight climate change by changing how food is produced, processed and consumed, while targeting market-rate financial returns. **Company's own description (paraphrased from its 2026 investor materials and website).** Newtree Impact presents itself as an investment holding that pairs financial returns with environmental impact. It invests in disruptive technology companies reshaping food systems, organised around three themes: Food-Tech (ingredients and dietary shifts), Agri-Tech (agricultural innovation) and Food-Loss (waste streams and upcycling). It invests at Series A to growth stage using its own impact methodology, which is inspired by the UN Sustainable Development Goals and measured with IRIS+ metrics. The company stresses that it is a holding company and not an investment fund: it invests for its own account and says it does not primarily aim to profit from selling its participations (OGM, 2 Jun 2026; Newtree Impact Investors page). **Independent characterisation.** In economic terms the vehicle works like a small, permanent-capital venture fund wrapped in a listed company. Its value lies almost entirely in unlisted minority stakes valued under IPEV guidelines; BDO built its valuation tool and policy. It carries cash on the balance sheet, earns negligible operating revenue and pays its costs (about €0.6M a year) out of capital. Shareholder returns depend on (a) uplifts in portfolio valuations, (b) eventual exits, which the company says will first clear accumulated losses and then be distributed, and (c) whether the share price trades at a premium or discount to NAV on a very thin Euronext Access order book. The legal emphasis on "holding, not fund" places it outside the Belgian and EU collective-investment rules (AIFMD) that would otherwise apply, which keeps costs low but also reduces the formal investor protections a regulated fund would offer. ### Business and revenue model | Revenue / value source | Description | Materiality | |---|---|---| | Unrealised valuation changes | Periodic IPEV-based re-measurement of participations, reflected in NAV but not in Belgian GAAP profit (only write-downs are booked) | Main driver of NAV. Revaluations were +€1.0M (2023), −€1.4M (2024) and −€2.8M (2025) per the NAV bridge. | | Realised gains on exits | Sale of participations | None disclosed to date | | Interest income | Return on cash | €95k (FY2024); €34k (FY2025) | | Operating revenue | Minor service and other income | €5k (FY2024); €32k (FY2025) | | Fees from investors | None. The holding does not charge shareholders management fees or carried interest. Costs are borne by the company; the term sheet cites an annual cost of about 2% of total equity and no carry. The Spreds offer states costs are capped at 1.75% of NAV once NAV exceeds €25M. | OGM 2026 term sheet; Spreds | **Product / service / subscription / licensing mix:** not applicable. The company has no product, subscription or licensing revenue at the holding level. The only operating products in the wider group sit in portfolio company Newtree Group SA (chocolate, spreads and office coffee). ### Value-chain position, "customers" and end-markets **Value-chain position:** a growth-stage capital provider positioned between seed and angel investors and late-stage, strategic or IPO investors. It frequently co-invests alongside specialist VCs and corporates (for example Bel Group, Danone Ventures, PINC, Big Idea Ventures, Beyond Impact). **"Customers" on the capital side:** about 750 or more shareholders, comprising founders, family offices, angels, institutions (Wallonie Entreprendre, SFPIM, Noshaq, Whitestone Group, among others) and retail investors who came in through crowdlisting campaigns on Spreds and Ecco Nova (BE and FR). **"Customers" on the asset side:** entrepreneurs in Food-Tech, Agri-Tech and Food-Loss. **End-markets indirectly exposed:** alternative proteins (plant-based, fermentation, insect), food ingredients (fats, flavours, egg and dairy proteins, cocoa alternatives), precision agriculture, pollination and biodiversity services, aquaculture, animal health (bacteriophages), food-waste analytics, and premium consumer chocolate and coffee. ### Operating model and cost base The holding runs with five operational staff, an Investment Committee of five external members, a Mission Committee of four and a Board of seven. Operating expenses were €573k in FY2025 (salaries €462k, rent and supplies €28k, other €74k, listing fees €9k), plus €57k of depreciation (FY2025 income statement). Management puts opex at 2.3% of NAV in 2025, against 2.2% in 2024 and 2.1% in 2023 and 2022.

RevenueN/A
Employees5
Market CapN/A
Founded2001
United States, North America
Netcare

Netcare Limited

Premium
Information Technology

Netcare is South Africa's largest private hospital operator. In the Competition Commission's Health Market Inquiry, it held about 31% of private hospital beds and 33% of admissions on 2016 data. Its operations are entirely in South Africa. They form an integrated ecosystem of 49 acute hospitals, the country's largest private mental health network (Netcare Akeso), pre-hospital emergency services (Netcare 911), cancer care, primary and occupational healthcare (Netcare Medicross, Netcare Occupational Health), prepaid and gap-cover products (NetcarePlus), point-of-care diagnostics, nursing and paramedic education, and an equity-accounted renal dialysis joint venture (National Renal Care). After leaving the UK in 2018, the group has pursued a ten-year, three-phase strategy launched in 2018: digitisation, data/AI-driven care, and person-centred care. It completed an ecosystem-wide electronic medical record in 2024. Since FY2022 it has expanded EBITDA margins every year, and it returns surplus cash through dividends (50–70% of adjusted HEPS) and a buyback programme that started in September 2023. Founder-CEO Dr Richard Friedland retires on 31 December 2026 and will be succeeded by Melanie Da Costa. --- **Company's own description.** In its FY2024 annual financial statements, Netcare describes itself as a leading provider of private healthcare services in South Africa. It provides acute services across a national hospital network and is the market leader in acute mental health. It also provides emergency, cancer care, diagnostic support, primary care and renal care services, plus occupational health and wellness. It aims to widen access to affordable care through NetcarePlus products and vouchers, and Netcare Education trains nurses and emergency medical personnel (S3, FY2024). The directors' report describes Netcare Limited as an investment holding company. Through subsidiaries, joint arrangements and associates in Southern Africa, it runs a private hospital group offering general, emergency and specialised care, with ancillary primary care, administration and logistics businesses (S3, FY2024). **Reporting structure.** Netcare reports two segments: 1. **Hospital and emergency services.** This is about 97.5% of FY2025 revenue. It is split into: - **Hospital and pharmacy operations:** the acute hospital network, day clinics and institutional pharmacies. - **Non-acute services:** Netcare 911, Netcare Akeso mental health clinics, Netcare Cancer Care, Netcare Diagnostics, NetcarePlus product and voucher sales, and (from June 2025) Quro Medical hospital-at-home. 2. **Primary Care.** This is about 2.5% of FY2025 revenue. It covers Netcare Medicross primary healthcare and dental centres, employee health and wellness (Netcare Occupational Health), and administrative services to medical and dental practices. **Revenue model.** Netcare does not report revenue split by product versus service. Its revenue recognition notes (S3, FY2024) show the following mechanics: **Hospital and pharmacy (about 90% of revenue):** ward, theatre and equipment fees, plus pharmaceuticals and consumables used during treatment. Revenue is recognised over the patient's stay. Most is paid by third-party medical schemes under annually negotiated tariffs, including lower-tariff Designated Service Provider (DSP) and restricted-network contracts. Cost of goods sold was R6,965m in FY2025, or 26.4% of revenue. This shows that dispensed medicines and consumables are a large part of billed value. **Emergency services:** recognised once a contract exists with the patient or next of kin. In an emergency, no contract exists at the time of service. **Mental health:** contract-based per-patient revenue. **NetcarePlus:** prepaid vouchers and procedures are recognised when redeemed. Gap cover products are underwritten by a third-party insurer (Hollard). **Netcare Diagnostics:** fees for administrative and logistics services to a third-party pathology practice. **Cancer care:** a substantial part is operating-lease rental of oncology assets. **Primary Care:** practice administration fees and per-visit treatment revenue. Occupational health revenue is earned under corporate contracts. **Other income:** property rental income from doctors' rooms, pharmacies and retail tenants on hospital sites. This was R454m in FY2025 (S2, segment note) and R435m in FY2024. There is no subscription or licensing model of significance. NetcarePlus prepaid products and GapCare have subscription-like features but are not separately sized. **Value-chain position.** Netcare is a provider. It owns most of its hospital real estate. Land and buildings had a carrying value of R11.2bn and an independent fair value of R22.2bn at 30 September 2024 (S3, FY2024). It does not employ most specialists. Under South African rules, specialists are independent practitioners who hold admission rights. Netcare employs nurses, pharmacists, paramedics and support staff. Upstream, it buys pharmaceuticals, consumables and medical equipment. Downstream, it is paid mainly by medical schemes (funders), with some out-of-pocket, corporate (occupational health) and public-sector or uninsured (NetcarePlus) revenue. **Customer types and end markets.** - Insured private patients (medical scheme beneficiaries). This is the dominant group, in a market of about 9.17 million scheme beneficiaries in 2024. - Medical schemes and administrators as contracting counterparties (for example DSP networks). - Employers (occupational health contracts). - Employed but uninsured households (NetcarePlus). - Government, through emergency services and historic public-private partnerships. The Lesotho PPP was terminated in August 2021. - Independent specialists and GPs who choose where to admit patients. **Independent characterisation.** Netcare is a mature, high-fixed-cost, volume-sensitive hospital operator in a concentrated but slow-growing insured market. Its earnings growth since FY2022 has come mostly from margin expansion and per-share accretion, not from volume: - Total paid patient days (PPD) grew only 0.7% in FY2025 and about 1.6% in FY2026. - Normalised EBITDA margin rose from 15.2% (FY2021) to 18.6% (FY2025), helped by digitisation savings and lower strategic and diesel costs. - About 10.4% of shares were repurchased between September 2023 and FY2025. Its strategic distinctiveness rests on four things: an integrated multi-service ecosystem, the first fully implemented ecosystem-wide EMR in Africa, the only four private Level 1 trauma centres accredited by the Trauma Society of South Africa, and leadership in private mental health.

RevenueN/A
Employees18,000
Market CapN/A
Founded1996
United States, North America
Mpact

Mpact Limited

Premium
Information Technology

Mpact is southern Africa's largest integrated paper and plastics packaging and recycling group, generating R14.0 billion of revenue in FY2025, roughly 89% of it in South Africa. Its model is vertically integrated around a closed loop: Mpact Recycling collects recovered fibre and other recyclables (639 million kilograms in 2025), the paper mills at Felixton and Mkhondo convert fibre into containerboard, and the Paper Converting arm turns board into corrugated packaging, with roughly 45% of its customers in agriculture — export citrus, deciduous fruit and grapes in particular. A smaller Plastics segment (about 15% of revenue) produces PET preforms, bottles, closures and large injection-moulded products such as Jumbo Bins® and crates. Having completed a heavy capital cycle (most notably the Mkhondo mill upgrade), management has pivoted towards harvesting returns, cutting debt and pruning weak assets — evidenced by the 2026 closure of the Springs coated cartonboard machine and recycling-site rationalisation. --- ### Company's own description In its FY2025 reporting Mpact describes itself as the largest paper and plastics packaging and recycling business in southern Africa, with an integrated model that spans raw material production, conversion, recycling and beneficiation, intentionally designed to close the loop in paper and plastic packaging [S1][S3]. Its stated purpose is to provide customers with innovative sustainable packaging, give effect to the circular economy through the integrated model, and make a difference in host communities [S3]. ### Operating units The FY2025 annual financial statements identify five operating segments — Paper Manufacturing, Paper Converting, Recycling, FMCG Plastics, and Bins & Crates — aggregated into two reportable segments, Paper and Plastics, with a Corporate cost centre [S2]. **Paper Manufacturing:** three mills: Felixton (KwaZulu-Natal; 100% recycled-fibre containerboard), Mkhondo/Piet Retief (Mpumalanga; semi-chemical virgin-fibre fluting plus, from late 2025, sodium lignosulfonate powder), and Springs (Gauteng; cartonboard and coreboard — coated BM6 closed May 2026, uncoated BM3 continues) [S5][S24]. About 25% of mill output (by tonnes) is sold to Mpact's own converting plants; 75% is sold externally, with roughly 12% exported, mainly within Africa. The top ten external paper customers account for about 72% of external paper-manufacturing sales [S3]. **Paper Converting:** nine corrugated plants in South Africa, one in Mozambique and two in Namibia; the 51%-owned Detpak (quick-service-restaurant cups, cartons, bags, napkins, trays, clamshells); 74%-owned Seyfert Corrugated Western Cape; and the Freshpact range of fibre punnets and trays [S3][S24]. **Recycling:** Mpact Recycling (14 operations through 2025, being rationalised in 2026) collects paper, cardboard, glass, cans, plastics and liquid board packaging; around 75–76% of recovered paper is consumed by Mpact's own mills, the remainder sold externally. Mpact Waste Management provides on-site waste services [S3][S24]. **FMCG Plastics:** PET preforms, bottles and wide-mouth jars (Wadeville), bottles/containers/closures (Pinetown, Atlantis) for food, beverage, pharmaceutical, household and cosmetics customers [S24]. **Bins & Crates (Mpact Plastic Containers, MPC):** Jumbo Bins®, plastic pallets, wheeled bins and crates from Castleview, Brits and Atlantis; a buy-back and exchange model sources around 30% of polymer from recovered product [S3][S24]. ### Business and revenue model | Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---|---| | Goods revenue (R'm) | not split | 12318.5 | 12760.8 | 13196.4 | 13846.3 | | Services revenue (R'm) | not split | 54.7 | 62.3 | 94.3 | 108.3 | Mpact's revenue is overwhelmingly product sales recognised at a point in time; a small services line (waste management) is recognised over time. *FY2021 split not disclosed in retrieved filings; the row is retained only for completeness — chart from FY2022.* [S2][S9] There is no subscription or licensing revenue. Pricing is predominantly negotiated contract pricing, with paper selling-price resets historically implemented around the fourth quarter (e.g., the end-2021 and end-2022 increases cited in results) [S10][S11]. No customer exceeds 10% of group external revenue [S2]. ### Value-chain position and end-markets Mpact sits across the upstream (recovered-fibre collection, virgin pulping at Mkhondo, paper making), midstream (corrugating, printing, injection and blow moulding) and post-consumer recovery stages. End-markets are agriculture (export fruit — citrus, pome, grapes, stone fruit, avocados, berries — and vegetables), FMCG (food, beverages, dairy, meat, poultry, personal and home care), quick-service restaurants, industrial and automotive packaging, municipalities (wheeled bins), retail logistics (returnable transit packaging) and export packaging-paper customers [S3][S24]. ### Independent characterisation Mpact is best understood as a domestically concentrated, mid-cap, integrated containerboard-and-corrugated producer with a secondary rigid-plastics business. Its earnings are driven by (i) the spread between containerboard selling prices (set at import parity in an oversupplied global market) and recovered-paper, energy and labour costs; (ii) export-fruit carton volumes, which are partly insulated from South African consumer weakness; and (iii) mill utilisation and utility reliability. The company has a heavy fixed-cost base, so operating leverage cuts both ways: ROCE fell from 18.5% (FY2022) to 9.2% (H1 2026 annualised basis as reported) as a large capex cycle coincided with a global paper downturn [S3][S5]. A unique governance overlay — a hostile 34.8% shareholder (Caxton) and a ~11.5% shareholder that is also a customer/competitor — has shaped corporate actions since 2021 [S2][S18].

Revenue$0.8B
Employees4,540
Market CapN/A
Founded2004
United States, North America
Astra

Astra Exploration Inc.

Premium
Information Technology

Astra Exploration Inc. is a Vancouver-based, pre-revenue precious-metals explorer. It began life as Momentous Capital Corp, a TSXV capital pool company, and became Astra through a January 2022 reverse takeover. The company has repositioned from a northern-Chile epithermal story (Pampa Paciencia) into a high-grade gold-silver discovery play in Argentina's Deseado Massif. There it has earned an 80% interest in La Manchuria from Patagonia Gold and holds an option to reach 90%. Since 2025, drilling at La Manchuria has returned bonanza-grade silver-gold intercepts. The company has expanded the claim package roughly sevenfold, to ~39,000 hectares, and raised over C$21 million in two bought-deal financings in 2025–2026. A second leg is Don Mario, a 100%-owned high-sulphidation gold target in Chile's Maricunga belt, now drill-ready. With ~C$12.5 million in treasury (September 2026), no debt and a 10,000–20,000 m campaign beginning November 2026, Astra is a funded, catalyst-dense, binary discovery-stage equity. --- ### What the company does Astra Exploration acquires, explores and seeks to advance epithermal gold-silver properties in South America. Its stated geographic focus is proven precious-metals belts in Argentina (Santa Cruz Province, Deseado Massif) and Chile (Antofagasta region Paleocene belt; Maricunga belt). The company generates no revenue. Its "product" is geological knowledge, meaning drill-confirmed mineralisation that may eventually support a mineral resource estimate. Value is realised through re-rating of the equity, sale of the asset, a joint venture, or (much later and less commonly for juniors) development. ### Company's own description (paraphrased from recent releases) In its 2025–2026 news releases, Astra describes itself as a precious-metals explorer with a portfolio in Argentina and Chile, headlined by: - the La Manchuria low-sulphidation epithermal (LSE) gold-silver project in Santa Cruz, Argentina, held under an option to reach 90% from Patagonia Gold. It sits in the Deseado Massif, a district that hosts Cerro Vanguardia and Cerro Negro; - the Pampa Paciencia gold-silver project (100%), in northern Chile's Paleocene belt near the Spence and Sierra Gorda mines; - the Don Mario project (100%; renamed from Cerro Bayo), in the Maricunga belt about 20 km from the Refugio mine. ### Independent characterisation Astra is best understood as a single-asset-led, discovery-stage explorer with an optionality tail: **Core value driver (≈ all of the current valuation):** La Manchuria. Here, historical drilling and a legacy (non-current, Patagonia-era) resource demonstrated a high-grade vein system. Astra's 2025–2026 drilling has extended it laterally and at depth and added new zones (Basalto, Eastern, Manchuria Hill). **Second option:** Don Mario. This is an early-stage, high-sulphidation (HSE) target in a district known for large deposits (Salares Norte, La Coipa). First drilling is planned for Q1 2027. **Legacy asset:** Pampa Paciencia. This was the founding asset; it is now de-emphasised but permitted (EIA approved January 2024). It carries both an epithermal vein story and a separately identified copper-porphyry target. ### Revenue model and value-chain position | Dimension | Characterisation | |---|---| | Revenue model | None (pre-revenue). Funded entirely by equity issuance (private placements, bought deals, warrant exercises) | | Product/service/subscription/licensing mix | Not applicable. 0% across all categories | | Value-chain position | Upstream: grassroots-to-advanced exploration. No resource estimate (NI 43-101) prepared by Astra; La Manchuria carries a historical, Patagonia-era estimate (see Section 5) | | Customer types | No customers. Prospective "buyers" of the outcome are mid-tier and major gold/silver producers (M&A acquirers) and equity investors | | End-markets | Gold and silver (global commodity markets). Indirect copper exposure via the Pampa Paciencia porphyry target | ### Business model mechanics Astra converts equity capital into drill metres and geological data. Value creation depends on three things: (i) grade × width × continuity of intercepts, (ii) cost per metre and discovery cost per ounce, and (iii) dilution management. Share count rose from under 23 million fully diluted at the QT (planned) to ~137 million by mid-2026. Two structural features are notable: 1. **Earn-in economics at La Manchuria.** Astra earned 80% by spending a modest, staged US$3.0 million total. Patagonia Gold's 20% is carried until a NI 43-101 resource of at least 1 Moz AuEq (indicated + inferred) is published. Astra can reach 90% with a US$5 million payment by the end of year six (Sources: Newsfile, 9 July 2024; Mining Technology, July 2024). 2. **Low-cost targeting before drilling.** At Don Mario the company used CS-NSAMT geophysics, LAG sampling, TerraSpec spectral work and WorldView-3 satellite alteration mapping to de-risk targets before committing drill capital (Newsfile, 30 June 2026 and 6 October 2026).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2020
Vancouver, Canada
Metrics

Metrics in Balance N.V.

Premium
Information Technology

| Field | Detail | Source | |---|---|---| | Legal name | Metrics in Balance NV (Naamloze Vennootschap; French: SA) | NBB FY2024 filing | | Former names | None identified | NBB filings; KBO extract referenced on IR site | | Founding / incorporation | Directors' mandates start 25 Oct 2016. Crossroads Bank for Enterprises (KBO) start date 28 Oct 2016. Some aggregators cite a deed publication of 3 Nov 2016. | NBB FY2022/FY2024 filings; Companyweb; Staatsbladmonitor | | Founders | Guy De Vreese, Marc Gryspeerdt, Philippe Van Acker | TradingView company profile | | Incorporation jurisdiction | Belgium. Register of Legal Entities (RPR) at the Enterprise Court of Ghent, Ghent division. | NBB FY2024 filing | | Enterprise / VAT number | 0665.584.108 / BE0665.584.108 | NBB FY2024 filing | | LEI | 9676001O8J81JR4HH394 | IR website | | Registered office / HQ | Zuiderlaan 1-3, box 8, 9000 Gent, Belgium. Shared with Remedent NV. Some aggregators list Melle, BE, which conflicts with the filings. | NBB FY2024 filing; IR website; TickerSpark | | Exchange / market | Euronext Access Paris (MTF, not a regulated market) | Euronext listing showcase; IR website | | Ticker | MLMIB (MLMIB.PA) | Euronext; IR website | | ISIN | BE0974328602 | Euronext; IR website | | CUSIP | Not applicable / not publicly disclosed | — | | FIGI | BBG00KB6ZGH7 | sustainabilityreports.com | | PEA / PEA-PME eligibility | Yes / Yes (per French broker data) | Easybourse | | Listing date | 15 March 2018 per IR website. The Euronext showcase records the operation date as 20 March 2018. | IR website; Euronext | | Listing method / price | Technical admission (private-placement category), 2,050,000 shares at EUR 5.65, valuation EUR 11.6m | Listing press release, 16 Mar 2018 | | Listing sponsor (2018) | Genesta (Hervé Guyot) | Listing press release, 16 Mar 2018 | | Fiscal year end | 31 December | NBB filings | | Shares outstanding | 4,390,543 registered shares per NBB FY2022/FY2024 filings. The IR website says 4,390,523; Easybourse says 4,390,520. | NBB; IR website; Easybourse | | Share capital | EUR 12,438,001 (IR site: EUR 12,438,001.27) | NBB FY2024 filing; IR website | | Employees (parent) | 0 FTE (FY2024). No staff costs booked in FY2021–FY2024. Historic: c.1.8–2 employees in FY2018–FY2019. | Companyweb; NBB filings; FinCheck | | Employees (group) | Not publicly disclosed | — | | Auditor | None. | NBB FY2022 and FY2024 filings | | Market capitalisation | c. EUR 144.9k at the last available quote of EUR 0.033/share | Simply Wall St (accessed Oct 2026) | | Website | www.metricsinbalance.com | IR website | | Principal activity code (Belgium) | Rental and leasing of medical and paramedical equipment (Companyweb). Specialised retail of medical and orthopaedic goods (FinCheck). | Companyweb; FinCheck | The entity profiled is the one on the identification list. No name change or listing transfer has been identified. The ticker, ISIN, website and Belgian domicile all match. | Metric | FY2018 | FY2019 | FY2022 | FY2023 | FY2024 | |---|---|---|---|---|---| | Employees, parent entity (headcount/FTE) | 2 | 2 | — | — | 0 | | Staff costs, parent entity (EUR) | — | — | 0 | 0 | 0 | *Sources: FinCheck (FY2018–FY2019); NBB filings (FY2022–FY2024 staff-cost line empty); Companyweb (FY2024 0 FTE).* Metrics in Balance N.V. is a Ghent-based micro-cap holding company. It began as a dental-occlusion diagnostics and custom-splint concept and has since become a small operator of musculoskeletal clinics in the Netherlands. Its founding thesis was that a bad bite can disturb posture and cause pain elsewhere in the body. It combined third-party measurement devices (an intra-oral 3D scanner, a jaw-motion recorder, a 4D spine scanner and a foot-pressure scanner) into a branded diagnostic protocol, followed by custom splint therapy. From 2020 the operating focus moved to chiropractic and physiotherapy clinics under the Dutch "Balans" brand, run through a wholly owned Dutch subsidiary. A DNA-based lifestyle-testing venture ("DNA Talks") followed in 2022. The listed parent has negligible turnover, no employees, a going-concern caveat and a balance sheet dominated by an unimpaired EUR 12.26m subsidiary carrying value. Its market capitalisation is below EUR 0.2m, making it effectively an illiquid shell-like listing over a small private clinic business. --- ### What the company does MiB describes itself on its corporate website as a holding company with three positions: 1. **Balans healthcare clinics.** These are multi-disciplinary chiropractic and physiotherapy clinics in the Netherlands, run through Metrics in Balance Nederland B.V. In mid-2022 the website said the group owned and operated six clinics, in Eindhoven, Malden, Tilburg (two), Venlo and Horst. Venlo and Horst were acquired at the end of June 2022. A greenfield clinic in Rotterdam was planned for September 2022. The stated model was buy-and-build, targeting 20 clinics within 36 months and then other countries. 2. **DNA Talks: lifestyle testing.** This is a B2B2C model in which DNA-based lifestyle tests are sold through distributors and independent coaches. Gut-microbiome, blood-analysis and stress tests were described as "coming soon". DNA Talks was incorporated in Belgium in April 2022, and DNA Talks AG followed in Switzerland at the end of June 2022. 3. **Occluso-posture therapy.** This is the original MiB concept: measure occlusion and posture, then correct with custom splints. The website describes it as "being tested at the moment". *Source: metricsinbalance.com/company. The page content dates from mid-2022 and has not visibly been updated.* ### The Company's own description (statutory management report, FY2024) The board's FY2024 report to the 14 July 2025 AGM gives the following picture (paraphrased from Dutch): - During FY2024 the company focused further on the Dutch market. Its emphasis moved towards building out the "Balans" centres, meaning chiropractic and physiotherapy practices. - MiB describes itself as a company that performs body measurements starting at the teeth and ending at the feet, which allow a person's posture to be mapped. - The commercial focus was the treatment of mechanical back complaints in "Balans rug centra" (back centres), grounded in measurements from the MiB system. - Since the balance-sheet date, progress in the Netherlands has continued but has been slower than planned. - The company is working on diversification and on tapping an alternative segment. - R&D activity was minimal. ### Original concept (2018 listing document) The March 2018 listing press release framed MiB as a measurement-diagnosis-remediation concept for malocclusion. It measures without pain or radiation: - the teeth; - temporomandibular joint (TMJ) motion and its actual versus ideal position; - the spinal column; - foot pressure and balance. The devices named were a Condor intra-oral 3D scanner, a Freecorder, a Diers 4D spine scanner and a pedoscan. The release claimed that roughly 10–20% of posture problems are "ascending" (starting below) and 80–90% "descending" (starting above). The core monetisable product was custom dental splints: sports splints, protection splints, anti-stress splints and anti-bruxism splints. The stated ambition was to become the world's leading splint company. MarketScreener and Easybourse summarise the original model as three revenue streams: - sale of the medical devices associated with the concept; - royalties from practices using the "Metrics in Balance" brand; - production and distribution of custom dental splints. ### Business and revenue model | Revenue stream | Mechanism | Entity | Status (latest evidence) | |---|---|---|---| | Clinic patient fees (chiropractic, physiotherapy) | Fee-for-service. Dutch physiotherapy is partly reimbursed through supplementary insurance contracts. | Metrics in Balance Nederland B.V. and/or clinic entities | Operating. "Balans Fysio BV", Boschdijk 391, Eindhoven (balans-rugcentrum.nl email domain), is listed by insurer Zilveren Kruis as contracted for physiotherapy through 2027. Its legal link to MiB is not confirmed in filings. | | Ancillary products (insoles, posture wearables, supplements, mattresses) | Product resale within clinics | Clinic entities | Described in the July 2020 press release; revenue not disclosed | | Device sales / brand royalties | Equipment sale or lease plus royalty from licensed practices | Parent (historic) | Parent turnover of EUR 300 in FY2022 and FY2023 indicates this stream is dormant | | Custom splints | Product manufacture and sale | Parent (historic) | Concept "being tested" (2022). No disclosed revenue. | | DNA lifestyle tests | B2B2C via coaches and distributors | DNA Talks BV (BE); DNA Talks AG (CH) | 25 active coaches in NL and a France distribution contract signed (mid-2022). DNA Talks BV equity was negative at EUR -165,011 at end-FY2024. | | Intercompany services | Recharges to subsidiaries | Parent | Receivables from affiliates of EUR 90,126 (FY2024). Parent FY2024 turnover of EUR 30,100 is consistent with a one-off goods sale (purchases of EUR 30,000 in the same year). | **Mix:** The product / service / subscription / licensing split is not publicly disclosed at group level. At parent level, revenue is de minimis and irregular. ### Value-chain position, customers and end-markets | Dimension | Characterisation | |---|---| | Customer types | Patients with chronic back, neck and posture-related pain (B2C). Historically, dental and allied-health practitioners licensing the concept (B2B). Lifestyle coaches and distributors for DNA tests (B2B2C). | | End-markets | Dutch chiropractic and physiotherapy; European consumer lifestyle and genetic testing; dental occlusion and TMJ-disorder therapy (dormant) | | Geography | Operations in the Netherlands; holding in Belgium; a DNA Talks entity in Switzerland; a DNA Talks distribution agreement with France (2022) | MiB sits at the downstream, patient-facing end of the musculoskeletal-care value chain. It does not manufacture the diagnostic hardware, which comes from third parties (Condor, Diers and others). It integrates these devices into a branded protocol and monetises through clinic services and, in principle, splints and test kits. ### Independent characterisation On the evidence available, MiB is best understood as a listed holding shell over a small, loss-making private clinic subsidiary. - The listed parent's statutory accounts show EUR 300 of turnover in each of FY2022 and FY2023, and EUR 30,100 in FY2024. - Its EUR 12.26m of assets are almost entirely the carrying value of two 100% subsidiaries. Both report negative equity: Metrics in Balance Nederland B.V. at EUR -316,735 and DNA Talks BV at EUR -165,011, both at 31 Dec 2024. - No impairment has been booked. - The share has traded at EUR 0.03 with no reported movement over the past year (Simply Wall St). - The company's own website has not updated its press-release list since July 2020 or its business description since mid-2022. The diagnostic concept is intellectually distinctive. However, it relies on contested clinical claims linking dental occlusion to whole-body posture, and it has not demonstrated commercial traction at the listed-entity level.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2016
Gent, Belgium
Memiontec

Memiontec Holdings Ltd.

Premium
Information Technology

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---| | Employee wages and benefits (S$ M) | 6.6 | 7.6 | 9.4 | 0 | *Note: the FY2025 figure is shown as 0 only because the Group did not publish the economic-value-distributed table in the AR2025 extract reviewed; treat FY2025 as not publicly disclosed. G&A payroll costs were S$1.89M in FY2024 and S$1.58M in FY2025 (FY2025 results), and fell a further 37.5% year on year in 1H2026.* Memiontec is a Singapore-headquartered, founder-controlled micro-cap water engineering group that designs, builds, operates and, in Indonesia, co-owns water and wastewater treatment assets. The company built its reputation as a membrane and MEICA (Mechanical, Electrical, Instrumentation, Control and Automation) contractor to Singapore's national water agency PUB, delivering packages at Tuas South Desalination Plant, Kranji NEWater, Changi Water Reclamation Plant Phase 2 and the Deep Tunnel Sewerage System Phase 2. In Indonesia it combines EPC work with minority and majority equity stakes in five BOOT/TOOT concessions, partnered with state-linked entities such as Jakarta Propertindo, PT PP Infrastruktur and ITDC. The business peaked at S$66.9M revenue in FY2023, then fell into consecutive losses as fixed-price PUB contracts suffered prolonged construction and cost overruns. With S$2.8M of attributable equity at 30 June 2026, covenant waivers in place and reliance on CEO loans, Memiontec is now a balance-sheet repair and recurring-income transition story rather than a growth story. --- ### Company's own description In its Annual Report 2025, Memiontec describes itself as a one-stop water technology total solutions provider with more than 30 years in the water industry. It combines membrane filtration, ion exchange, and physical, chemical and biological treatment processes with in-house design, customised engineering and turnkey implementation. It states a presence in Singapore, Indonesia, China and Vietnam, serving both municipal and industrial customers. The company also says it creates shareholder value through long-term BOOT (Build-Own-Operate-Transfer) and TOOT (Transfer-Own-Operate-Transfer) investments that generate recurring income (AR2025, "About Us"). ### Business model and revenue model The Group reports four segments that together span the water value chain: 1. **TSEPC (Total Solutions with Engineering, Procurement and Construction)** is project-based, fixed-price contracting, with revenue recognised over time by stage of completion. It accounted for 83.8% of FY2025 revenue and 93.9% of FY2024 revenue (AR2025 Operating and Financial Review). 2. **OMS (Operations, Maintenance and Services)** is service revenue recognised over time. Contracts typically run 1–3 years. OMS on the Group's BOOT/TOOT concessions runs 20–25 years (AR2025 Synergistic Business Model). 3. **SDS (Sales and Distribution of Systems and Equipment, including trading)** is product revenue recognised at a point in time. It covers modular systems, components, chemicals and membranes, including products sold as an authorised distributor. 4. **SOW (Sales of Water)** is recurring, concession-style revenue from BOOT/TOOT projects where the Group is owner or co-owner. It is recognised at a point in time. A material part of the economic value sits outside consolidated revenue because several concessions are equity-accounted JVs or FVOCI investments. **Revenue mix by nature, FY2025 (S$'000, FY2025 results announcement):** project/service revenue recognised over time was 23,260 (TSEPC 21,753 + OMS 1,507), or 89.6%. Product and water revenue recognised at a point in time was 2,688 (SDS 2,230 + SOW 458), or 10.4%. The company has no subscription or licensing revenue. ### Value-chain position Memiontec sits in the midstream of the water value chain. It buys membranes, pumps, piping, instrumentation and civil/M&E subcontract services, adds in-house process design, PLC/control engineering and fabrication, and delivers turnkey plants. Downstream, it captures operating income through OMS and, in Indonesia, tariff-type income through concessions. It owns no membrane manufacturing IP. Its differentiation rests on process design know-how, licensing (BCA ME11 Grade L6 in Singapore; B1/B2 construction licences in Indonesia), and long-standing relationships with PUB and Indonesian state-linked partners (AR2024 Chairman and CEO's Message). ### Customer types and end-markets **Singapore public sector:** PUB is the dominant Singapore customer. Named projects include the C22C MBR contract at Changi WRP Phase 2 (S$56.6M), DTSS Phase 2 odour control and air jumper facilities (S$21.7M), Tuas South Desalination Plant ultrafiltration (S$33.2M), and Jurong Island STP M&E replacement. **Singapore other institutional:** Mandai Wildlife (penguin exhibit and bird park life-support systems) and Semakau Landfill (NEA-related floating wastewater treatment and power generation system). **Indonesian municipal:** city water and sewerage agencies (Palembang, Makassar, Jambi, Pekanbaru, Jakarta via PAM Jaya/Jakpro) and the tourism-estate utility ITDC (Nusa Dua, Bali). **Indonesian industrial:** agro-industry and palm oil (Dumai, WPS biodiesel effluent), food and beverage (Indolakto), mining (Amman Mineral townsite RO; Adaro intake relocation), and industrial estates (Suryacipta). **China:** trading of components through MIT Water Technology (Chengdu). Revenue is negligible (S$11k in FY2023; nil in FY2024–FY2025). **Vietnam:** a subsidiary was incorporated in October 2022 for construction of water supply and drainage systems. No disclosed revenue to date. ### Independent characterisation Memiontec is best understood as a sub-scale, founder-run specialty water contractor whose earnings are dominated by a small number of large, lumpy, fixed-price public tenders in Singapore. It also has a slower-burn Indonesian portfolio of co-owned concessions. The Singapore franchise is technically credible: the Group is one of the few local SMEs with unlimited-value ME11 L6 registration. However, the FY2024–FY2025 losses show that the Group carried construction-period and cost-escalation risk it could not pass through. The C22C and DTSS2 contracts, won in 2021–2022, absorbed post-pandemic labour, material and financing inflation. Indonesia has been the steadier contributor, but it generates modest absolute profits, carries IDR translation risk, and relies on contractual "Combination Agreements" rather than direct equity ownership for control of PT Memindo Pratama. The investment case now hinges on (i) collection of final accounts and certification of unrecognised variation orders on the Singapore projects, (ii) commercial operation of the Bali desalination BOOT and Tanah Merah BOOT, and (iii) whether the balance sheet can be stabilised without further heavy dilution.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1992
Singapore
MeGroup

MeGroup Ltd.

Premium
Information Technology

MeGroup is a family-controlled, Singapore-listed micro-cap whose entire operating base is in Malaysia. It combines two automotive businesses with very different economics. The first is a niche noise, vibration and harshness (NVH) component manufacturer. Founded in 1995 as a carpet and insulation supplier to Proton, it now supplies thermobonded-felt-based insulation, headliners and trunk systems to several Malaysian vehicle assemblers. It earns gross margins of roughly 24–28%. The second is a multi-brand retail dealership network in the Klang Valley. As of mid-2026 it runs 14 outlets across seven brands: GWM, Honda, Omoda & Jaecoo, Jetour, Mazda, MG Motor and Mitsubishi Motors. Dealership gross margins are below 10%. Dealerships generate about 82% of revenue. Manufacturing generates roughly 36–39% of gross profit. Group returns therefore swing with Malaysian vehicle demand, model-cycle timing at OEM customers and dealership margin pressure from new Chinese entrants. The group is small (FY2026 revenue RM342.0m) and carries meaningful debt (net debt including leases RM78.1m). It trades well below book value (P/B ≈0.5x). --- ### Company's own description (AR2026, paraphrased) AR2026 describes MeGroup as an automotive group with two activities: - the manufacture of NVH and non-NVH components for automobiles; and - the operation of automobile dealerships in Malaysia. The Manufacturing Business organises its output into two catalogues: **NVH catalogue:** dashboard insulators, outers, hoods, headliners, undercovers and wheel arches. **Non-NVH catalogue:** board assembly decks, trunk lids, package trays and deck boards. The Dealership Business retails new vehicles from GWM, Honda, Omoda & Jaecoo, Jetour, Mazda, MG Motor and Mitsubishi Motors. It does so through 3S and 4S dealerships in Kuala Lumpur and Selangor that the group owns and operates. ### Business model and revenue model | Dimension | Manufacturing Business | Dealership Business | |---|---|---| | Revenue type | Product sales (build-to-specification components) | Product resale (new vehicles), service (after-sales maintenance and repair), parts and accessories sales, commissions (insurance), leasing (Flux MaaS) | | Customer type | OEMs and vehicle assemblers in Malaysia; one HVAC OEM (Johnson Controls Hitachi) | Retail consumers and corporate buyers in the Klang Valley | | Contract structure | Components are customised per model and usually supplied for the entire life cycle of a car model (company website) | Dealer agreements with brand principals or distributors, typically fixed-term and renewable (e.g. Mazda dealership renewed for three years in 2019; MG appointment initial term of 36 months plus a 24-month option) | | Gross margin (FY2026 / FY2025) | 23.7% / 25.7% (AR2026) | 9.2% / 9.3% (AR2026) | | Share of FY2026 revenue | 18.1% | 81.9% | | Share of FY2026 gross profit | 36.3% (RM14.64m of RM40.34m) | 63.7% (RM25.70m) | **Revenue model mix (independent characterisation).** - New-vehicle resale is the volume engine of the dealership segment. In 1H FY2025, automobile sales were RM136.2m of the segment's RM152.5m (≈89%), per the November 2024 media release. - After-sales service, parts, body-and-paint and insurance commissions make up the remainder. These carry much higher margins. - Manufacturing is pure product revenue. - There is no material subscription or licensing revenue. The acoustic test lab offers third-party testing services, but revenue from it is not disclosed. ### Value-chain position **Manufacturing:** a Tier-1/Tier-2 component supplier. It sits upstream of Malaysian assembly plants operated by national and foreign brands. It is vertically integrated into its key input, thermobonded felt, which it produces in-house from thermoplastic and non-thermoplastic fibres. Fibres are sourced from Malaysia, Thailand and Korea (website). **Dealership:** a downstream franchised retailer. It depends on principals and distributors for vehicle allocation, pricing, incentives and the duration of its franchise. ### End-markets - Malaysian passenger-vehicle market. Total industry volume (TIV) was 820,752 units in 2025 (MAA). - Malaysian vehicle production. Total industry production (TIP) was 747,780 units in 2025 (MAA). This drives demand for OEM components. - HVAC equipment (a single disclosed customer, Johnson Controls Hitachi). This is a minor diversification. ### Independent characterisation MeGroup is best understood as a profitable, niche component maker attached to a larger, lower-margin dealership business. **Manufacturing:** has real technical assets: an in-house felt line, an R&D lab and what the company describes as the only acoustic sound test lab owned by an NVH manufacturer in Malaysia (AR2026). It also has a technical-assistance relationship with Japanese NVH specialist Hirotani, which since July 2024 also holds a 3.2% stake in the manufacturing subsidiary. **Dealership:** has churned brands repeatedly. Since 2024 it has exited Hyundai, Proton, Ford and Peugeot and added MG, Omoda & Jaecoo, GWM and Jetour. This repositions the network toward fast-growing Chinese brands at the cost of franchise stability. **Group profitability:** is thin: net margin peaked at 1.9% in FY2024. Profitability is also sensitive to interest costs, because floor-stock financing and term loans fund inventory and property.

Revenue$0.1B
EmployeesN/A
Market CapN/A
Founded1995
Singapore
Marinomed

Marinomed Biotech AG

Premium
Information Technology

Marinomed Biotech AG was an Austrian science-driven biopharmaceutical company built on two proprietary platforms: Carragelose, an iota-carrageenan red-algae polymer with virus-blocking, allergen-blocking and moisturising properties, commercialised as an over-the-counter portfolio of nasal sprays, throat products and eye drops through roughly 20 licensing partners worldwide; and Marinosolv, a patented solubilisation technology that brings poorly water-soluble drugs such as budesonide and tacrolimus into aqueous solution, enabling lower doses, faster onset and preservative-free formulations for sensitive tissues like the nose and eye. After a first court-supervised restructuring in 2024, the company sold its revenue-generating Carragelose business to French CDMO Unither Pharmaceuticals for up to EUR 20 million, pivoting to an asset-light licensing model around Marinosolv (Budesolv, Tacrosolv, Satiasolv) and Solv4U services. Non-receipt of Unither earn-outs triggered a second insolvency in July 2026, culminating in court-ordered dissolution in September 2026. --- ### Company's own description (Annual Financial Report 2025) In its FY2025 annual report, Marinomed describes itself as a biopharmaceutical company focused on the invention, development and licensing of drugs, having achieved milestones in respiratory, infectious, immune and eye diseases based on patented platforms. Its stated model is to concentrate on what it does best — identifying substances and indications, early and mid-stage drug development, medical device development and partnering — while leveraging larger pharmaceutical partners for late-stage clinical development, regulatory management and marketing. Revenue may be generated through product sales, patents, data, licensing or similar transactions. Partners typically take over the entire commercial value chain from manufacturing to distribution in exchange for upfront, milestone and royalty payments, allowing Marinomed to remain "asset-light." The latest standard corporate boilerplate (July 2026) described Marinomed as an Austrian, science-based biotech company with a growing development pipeline that develops patent-protected products on the Marinosolv platform, which improves solubility and bioavailability of hardly soluble compounds for autoreactive immune disorders. ### Independent characterisation Marinomed was, in substance, a micro-cap European platform biotech that for most of its listed life financed R&D from a modestly profitable-at-gross-level OTC medical-device franchise (Carragelose), supplemented by EIB venture debt, convertible notes and small equity raises. The Carragelose franchise benefited from a pandemic-era demand spike (FY2021–FY2022 revenue of EUR 11.6m and EUR 11.3m respectively) but normalised in FY2023 (EUR 9.2m) and collapsed in FY2024 (EUR 4.7m) as partner ordering faltered and the company entered insolvency. The Marinosolv platform produced clinically validated assets — Budesolv met all endpoints in a Phase III trial for allergic rhinitis, and Tacrosolv showed Phase IIa efficacy — but late-detected room-temperature stability problems derailed partnering for years. From March 2025 onward, Marinomed had essentially no recurring product revenue, relied on a EUR 5m upfront from Unither, small service fees and successive dilutive micro-raises, and carried a fixed restructuring-quota repayment schedule it could only meet if contingent earn-outs materialised. They did not, and the company failed. ### Business model and revenue model mix | Revenue stream | Description | Status at dissolution | |---|---|---| | Product sales (Carragelose OTC) | Supply of finished Carragelose nasal sprays, lozenges and eye drops to ~20 licensees/distributors | Divested to Unither (closed 28 Feb 2025); remaining stock sold to Unither | | Licensing / milestones (Carragelose) | Licence fees and milestones from regional partners (e.g., Procter & Gamble for US) | Transferred to Unither with all contracts | | Licensing / milestones (Marinosolv products) | Upfront/milestone/royalty deals for Budesolv (Luoxin – Greater China; Swiss partner), Tacrosolv (none closed) | Assets to be sold by administrator | | Solv4U technology services | Fee-for-service feasibility and formulation studies; follow-on licences (Aché – Brazil, SPH Sine – China, Unither – France) | Ceased with operations | | Pharmaceutical services | Virological, immunological, toxicological assays; ex-vivo models (fee-for-service) | Ceased | | Transition service agreement | Regulatory, BD and R&D services to Unither post-closing | Ceased | | Compounding (announced Apr 2026) | Marinosolv-based solutions for compounding pharmacies; first revenues targeted Q4 2026/early 2027 | Never generated revenue | | Disposal proceeds / earn-out | EUR 5m fixed price received; up to EUR 15m earn-out contingent until mid-2027 | Earn-out disputed, not received | Quantified mix by stream is not publicly disclosed for FY2025 beyond the statement that EUR 5.0m of EUR 7.7m revenue was the Unither upfront and the remainder comprised delayed 2024 orders, inventory sale to Unither, other Carragelose-sale proceeds and Solv4U research revenue (Annual Financial Report 2025). ### Value-chain position, customers and end markets Marinomed sat in early-to-mid-stage drug and device R&D, outsourcing manufacturing (fill-finish via CMOs) and commercialisation. Customer types: (i) OTC pharmaceutical marketers and distributors (Carragelose era); (ii) mid-sized and large pharma licensees for Rx assets (Luoxin, Swiss partner, Phargentis); (iii) pharma/biotech formulation clients (Solv4U); (iv) planned compounding pharmacies. End markets: cough, cold and allergy consumer healthcare; allergic rhinitis Rx; ophthalmology (dry eye, inflammatory ocular surface disease, vernal keratoconjunctivitis); drug-delivery/bioavailability enhancement; respiratory inhalation (via Phargentis).

Revenue$0.0B
Employees32
Market CapN/A
Founded2006
United States, North America
Long4life

Long4life Limited

Premium
Information Technology

Long4Life was a JSE-listed, lifestyle-focused investment holding company. Bidvest and Bidcorp founder Brian Joffe created it in 2016–17 as a permanent-capital alternative to a closed-end private equity fund. It raised R2bn at its April 2017 listing. Within eleven months it assembled a portfolio of consumer businesses in three divisions. Sport and Recreation held Sportsmans Warehouse, Outdoor Warehouse, Shelflife and the Performance Brands apparel arm. Beverages held Chill and Inhle, which make Score Energy and Fitch & Leedes and run contract packing. Personal Care and Wellness held the Sorbet franchise, Lime Light distribution and ClaytonCare sub-acute healthcare. The group was cash-rich and almost ungeared, and at its peak in FY2020 reported revenue of R4.09bn. Its shares nevertheless traded at a persistent discount to net asset value. After a 2021 strategic review, management sold the group to Old Mutual Private Equity at R6.2249 a share. OMPE then broke up the portfolio and sold its parts to strategic and financial buyers between 2022 and 2025. --- ### The company's own description (paraphrased from the FY2021 Directors' Report) In its last full annual financial statements (FY2021), Long4Life described itself as a JSE-listed investment company with a lifestyle focus, aiming for superior medium- and long-term returns to shareholders. It invested in businesses with attractive growth prospects run by entrepreneurially minded management teams. The board saw its role as capital allocation and as an active participant in finding, approving and executing investments. The group ran a decentralised management model. It gave investee companies financial, strategic and management support, took a long-term view of its holdings, and kept the flexibility to sell investments that no longer met its criteria (FY2021 AFS, Directors' Report). The FY2019 results described the strategy as investing in leisure and lifestyle sectors across both "emerged" and "emerging" consumer markets. ### Independent characterisation Long4Life is best described as a listed, decentralised consumer conglomerate run on Bidvest-style principles. It combined a specialty retailer, a branded and contract beverage manufacturer, and a beauty franchisor with a small healthcare business. The group's economics were dominated by Sport and Recreation, which supplied 56–58% of revenue and, in FY2021, 86% of divisional trading profit before corporate costs (analyst-calculated: R317.3m of R406.9m positive divisional trading profit). The holding company's value proposition rested on four features: - capital-allocation discipline, including the group ROFE target of at least 35%; - the founder's deal-making reputation; - a large net cash pile, initially used to buy assets and later to fund share buybacks; - a target of sustained growth above 15% a year (Pre-listing statement, as reported by BusinessTech, 3 Apr 2017). In practice, the group stopped acquiring at scale after the Rage deal was abandoned in August 2018. From FY2019 it returned about R1.07bn to shareholders through buybacks (analyst-calculated: R159.6m + R426.5m + R485.7m). That pivot amounted to an admission that its own equity was the cheapest asset available. ### Business model and revenue model Long4Life earned revenue from five distinct models: 1. **Retail sale of goods** (point of sale). Sportsmans Warehouse, Outdoor Warehouse, Shelflife and online stores. 2. **Wholesale sale of goods.** Performance Brands sold apparel to third-party retailers, lodges and corporates. Chill and Inhle sold own-brand and private-label beverages to retailers and distributors. 3. **Services rendered over time.** Inhle and Chill provided beverage contract packing for third-party brand owners, recognised as units are produced. ClaytonCare provided sub-acute medical rehabilitation billed to patients and medical funders. Sorbet's corporate-owned stores provided grooming services. 4. **Franchise income, royalties and administration fees.** Sorbet earned sales-based royalties from franchisees. 5. **Rental income.** Immaterial. **Revenue by type (R m)** (FY2019–FY2021 audited) *Source: FY2020 Audited Provisional Summarised Results, note 4; FY2021 Audited AFS, note 3.1. The FY2021 rental income was R47,000.* **Product vs service mix (analyst-calculated from the table above).** Sale of goods was 81.9% of revenue in FY2019, 79.1% in FY2020 and 86.8% in FY2021. Services, franchise and rental income made up the rest. The FY2021 shift towards goods reflects COVID-19 closures in contract packing (beverage contract packing nearly halved) and in Sorbet services. There was no subscription or licensing revenue apart from Sorbet's franchise royalties. ### Value-chain position **Sport and Recreation:** was vertically integrated. Performance Brands designed and manufactured technical apparel, commissioning a new factory in 2018. It also held the exclusive distribution rights to third-party brands such as Speedo (from January 2020). A central distribution centre in Philippi, Cape Town, which the group bought in FY2021 for R106m, supplied the retail chains. **Beverages:** covered the whole chain from product conception and development through production, sales and marketing. Two plants, in Stellenbosch and Heidelberg, gave complementary capacity in cans and glass (Creamer Media, 28 Nov 2017; FY2019 results). **Personal Care and Wellness:** was asset-light. Sorbet was a fully franchised, owner-operator network. Lime Light distributed professional products to salons. ClaytonCare ran two sub-acute facilities. ### Customer types and end-markets | Customer type | Businesses serving them | End-market | |---|---|---| | Retail consumers (middle to upper income) | Sportsmans Warehouse, Outdoor Warehouse, Shelflife, Sorbet, Sorbet Man, Candi & Co | Sporting goods, outdoor/camping, sneakers and streetwear, beauty and grooming | | Wholesale and corporate buyers (retailers, lodges, corporates) | Performance Brands, Direct Leisure Golf, Chill (own brand and private label) | Technical apparel, golf equipment, packaged beverages | | Multinational and local beverage brand owners | Inhle and Chill contract packing | Energy drinks, carbonated soft drinks, water, alcoholic beverages | | Franchisees (small business owners) | Sorbet Holdings | Beauty franchise system | | Patients and medical funders | ClaytonCare | Sub-acute and post-acute rehabilitation | | Professional salons | Lime Light | Professional hair, beauty, waxing and grooming products |

Revenue$0.2B
Employees3,500
Market CapN/A
Founded2016
United States, North America

Page 207 of 482

1…206207208…482

Page 207 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo